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Abstracts of papers presented at the ISLAR
(International Symposium on Laboratory
Automation and Robotics) 1997
The 15th International Symposium on Laboratory Automation and Robotics was held from 19-22 October 1997 in
Boston, USA. State-of-the-art developments in laboratory automation and robotics were reflected in the symposium
programme, which included papers and posters on all aspects of the technology--drug discovery research, data handling
and data management, chemical analysis, re-engineering the laboratory, laboratory workstations, bioanalytical assays,
managing laboratory automation, dissolution testing, pharmaceutical analysis, automation and combinatorial chem-
istry, validating automated methods and advanced topics. We are printing abstracts of papers from ISLAR and we hope
that you find them informative and productive.
The 1998 ISLAR will be held in Boston, USA from 18-21 October 1998. Session topics will be similar to previous years,
but will also include high throughput screening, re-engineering the laboratory, and increasing productivity. For more
information, contact Christine O’Neil at 508 497 2224; fax on 508 435 3439; send an e-mail to islar@ISLAR.com or visit
the ISLAR pages at http://www.islar.com.
Technology and the new high-throughput drug
discovery paradigms
Andrew Shaw, Zeneca Pharmaceuticals, Wilmington, DE, USA
The development of powerful new research technologies
has led to greatly enhanced expectations of the discovery
phase of pharmaceutical research. However, as well as
bringing the promise of new efficiency, the rapid pace of
new technology development and implementation
constantly creates new bottlenecks in the research
process, threatens competitive obsolescence in the tech-
nology platform and creates questions about organiza-
tional structure. This presentation gave a personal
overview of the problems of creating and maintaining
an effective capability in the lead discovery phase of
research, while highlighting areas for technology
development.
Potential applications for laboratory automation
in drug discovery and development: a drug meta-
bolism perspective
Gerald T. Miwa, Dupont Merck Pharmaceutical, 2Vewark, DE,
USA
Analytical throughput capacity is a common limiting
resource in conducting pharmacokinetic studies.
Pharmacokinetic studies are an integral part of non-
clinical toxicology studies, as well as clinical pharma-
cology research. For many pharmaceutical companies,
pharmacokinetic studies are also becoming an integral
part of the drug discovery paradigm. In contrast to drug
development, where throughput requirements are
dictated by many samples from few compounds, drug
discovery is characterized by few samples from many
compounds. This difference affords new applications
for automation during drug discovery. The future
direction for these applications at DuPont Merck was
described.
Success is not necessarily automatic
Alastair Selkirk, Abbott Laboratories, North Chicago, IL, USA
The pharmaceutical industry needs to not only discover
new molecules but also to develop them as efficiently and
effectively as possible. Success is being first to market, not
necessarily first to proof of concept. To be successful,
development needs to reduce timelines while maintaining
quality and preventing burnout. While automation
obviously plays a very significant role in this approach,
many other factors must be in place for automation to be
as effective as possible. These factors include planning,
process optimization, organizational structure, people
development and the need to see the total picture.
This presentation discussed these factors and their rela-
tionship with automation. It evaluated less obvious areas
of automation, like document management, as well as the
more established ones and discussed the premise, that it is
the integration of all these aspects, including automation,
that truly offers the biggest opportunities.
Re-inventing drug discovery: issues and actions in
the quest for innovation and productivity
Pradip Banerjee, Andersen Consulting, Florham Park, 2VJ, USA
As it approaches the 21st century, the pharmaceutical
industry has re-emphasized its focus on innovative drug
discovery as the key to future success. Prioritizing in-
novation has become a strategic imperative in an increas-
ingly competitive environment, and the hurdles for
success are extremely high.
In order to sustain revenue growths at the 10% level that
the industry has historically produced, the major global
pharmaceutical players must average between 5-6 sig-
nificant (that is, with a sales potential of greater than
$350M/year) NCE launches annually in the future.
Andersen Consulting has conducted a study of how
pharmaceutical companies must restructure their drug
discovery programmes to develop the high performance
drug discovery processes necessary for future success. The
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objectives of the study were to understand the future
direction of the discovery research process, analysing the
impact of new technology, the implications for process
organization and management, and the goals that cut-
ting-edge discovery companies are setting themselves for
the future. A broad survey was undertaken of discovery
companies, with a representative sample of ten com-
panies ranging from the top-tier pharmaceutical majors,
through middle and lower tier players to biopharmaceu-
tical companies, in the US, Europe, and Japan. One
hundred interviewees covered all aspects of involvement
with the discovery process, among them senior manage-
ment of the R&D function and therapeutic areas, and
individuals in biological, chemical, development and IT
functions.
The Andersen Consulting study highlights the intimidat-
ing scale of the task facing discovery companies. In order
to maintain the goals set to maintain market competi-
tiveness, more NCE candidates for clinical development
must be produced, and faster. New goals set by com-
panies surveyed are a minimum of one NCE per 100
discovery research staff, and a doubling of the speed of
delivery of NCEs to clinical development, from up to
seven years to less than three. Quality must not be
compromised by quantity; company goals are more
development-ready compounds to lower the attrition rate
of clinical development, and, ultimately, to ensure that
the launch of truly innovative products to reap maximum
reward on investment.
The effective exploitation of the new technologies trans-
forming the drug discovery process will be a key to
meeting these goals. It is clear from Andersen Consulting
research that the key to high performance drug discovery
is as much about the development of effective processes,
information management, and people organization as it
is about new technologies. Andersen Consulting has
developed recommendations for an approach to high
performance drug discovery which optimizes the inter-
action of these elements.
Effective co-ordination of technology, process and people
will require an IT integration strategy which optimizes
the potential of all three. Knowledge, rather than in-
formation management must be the key goal, with
comprehensive and integrated applications to support
the whole process from target generation and character-
ization, lead identification and optimization, and the
discovery/development interface.
Placing and preserving priorities: projects, pro-
ductivity, progress and people
John Babiak, Wyeth-Ayerst Research, Princeton, NJ, USA
Robotic High Throughput Screening (HTS) within
pharmaceutical companies has become a valuable re-
source to search for proprietary chemical structures
which interact with novel biomolecular targets such as
enzymes, cellular receptors or ion channels. Under some
circumstances these chemicals may serve as leads which
can be optimized into marketable drugs. To maximize
success it is necessary to use HTS in a manner which
complements and facilitates the changing priorities of
drug discovery research.
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Numerous forces compete for the limited resources of a
HTS group. Major factors which can influence priorities
are projects, productivity, progress and people. The
challenge to the HTS group is to provide excellent and
timely screening services, while continuing to devote
efforts to new technologies and personnel development.
There are a great variety of issues considered by senior
management in determining the priority of the project
associated with a particular screen. Examples include the
medical need for a treatment, anticipated market size for
the expected drug, the status of related activities by
competitors, validity of the molecular target as a med-
iator of the disease and perceived case of development.
Since it is often the case that the projects with the greatest
potential rewards have the lowest probability of success,
it is not surprising that priorities among projects can
change dramatically and quickly.
HTS groups are frequently evaluated by numerical
measures of productivity, such as samples tested per week
and number of screens completed per year. Naturally,
this emphasis on throughput encourages the HTS group
to prioritize in favour ofscreen designs which are easier to
implement and run. Although in many cases conversion
of assays into preferred screen formats will improve
efficiency, some molecular targets may be deprioritized
because they will decrease the perceived productivity of
the HTS group.
Progress in developing new technologies and a commit-
ment to development of the people within the HTS
organization are two other factors which must also
influence the setting of priorities. Evaluating and intro-
ducing new technologies--hardware, software, assay for-
mats--is time consuming and reduces productivity in the
short term. When successful, however, the results may be
improved productivity or the ability to perform screens
previously deprioritized for being too difficult.
People development must be a major concern, because it
is the people who develop and implement the new
technologies and determine how productive the robotics
and automated equipment will actually be. HTS is most
successful meeting the priorities for drug discovery re-
search through the ability of the people in the HTS group
to understand the needs of investigators on a variety of
drug discovery projects, and the progress derived from
the new technologies and to achieve the highest level of
productivity possible.
Planning and establishment of a high throughput
screening site
Julie j. Tomlinson, Brent T. Butler, Joan Frezza, Albert A.
Smith, and W. Blaine Knight, Molecular Biochemistry, Glaxo
Wellcome, Research Triangle Park, VC, USA
During 1966 and 1997 Glaxo Wellcome US Research
planned and implemented a new strategy. In the first
quarter of 1996, 13 cross-functional work groups planned
specific, individual components of the strategy and
submitted reports detailing their plans to management.
Management used the reports to devise an overall
implementation plan, then Research was reorganized
and implementation of the strategy commenced.Abstracts of papers presented at the 1997 ISLAR
An important part of the strategy entailed development
of two automated high throughput screening (HTS) sites
in Research Triangle Park, NC. Both screening sites are a
part of the Biochemistry division, one in a primary R&D
complex and the other in a satellite building several miles
away. This presentation described the set-up of the site in
the satellite building.
Site set-up entailed hiring and training people, building a
new laboratory and modifying existing labs, purchasing,
installing and implementing automated systems and
developing the process required to sustain compound
handling with high throughput screening operations.
All of these aspects of the screening site were developed
and implemented simultaneously and successfully during
1996 and 1997.
Making laboratory automation work for HTS
Carol Ann Homon, Boehringer Ingelheim Pharmaceuticals, Inc.,
ig, c, gs
HTS today is quite different from what it was 10-12
years ago. Then, the goal was to screen a subset of the
company’s compound collection of 10 000 compounds or
so. There was not a tremendous push to get these
compounds tested, since not all scientists were firm
believers in the HTS concept and not all programmes
took advantage of HTS. Originally, an HTS laboratory
could meet its throughput demands with a few simple
automated pipetting machines such as the Tecan 500
series. These little machines turned out to be incredibly
reliable workhorses. However, as HTS emerged as a
successful new approach to new drug discovery, it
became clear that more than a select few compounds
needed to be screened. Companies started screening their
entire collections ranging from 100 000 to 200 000 com-
pounds or more. There also evolved a need to have
screening results sooner so throughputs quickly rose.
The higher throughputs required more automation,
and in some cases, full robotic applications could be used
to gain 16-24 hour a day operation. Problems for these
systems came when they were required to do too many
different types of assays. It became clear that each assay
had its particular automation requirements. It was
necessary to establish a system dedicated to each type
of assay to provide a more robust and reliable system.
Even so, laboratory robotics had and still has problems.
HTS assays were simplified and reduced to pipet and
quantitate assays whenever possible. These homogeneous
assays are highly dependent on the robotic pipetting
device and on the quantitation device. The throughput
is determined by how rapidly these steps are performed.
Robotic pipettors have evolved to at least 8-tip instru-
ments with 96-tip pipettors gaining a major foothold in
HTS laboratories. The robotic pipettors are truly the
heart of the HTS effort. In some cases, it has become
necessary to have the pipettor built within the machine
such as with FLIPR which is a fluorescent imaging
system for whole cell assays. These specialized ’work-
station’ type devices need to be available within the HTS
laboratory since a wide variety of cellular and molecular
assays make up the assay profile in HTS.
The more recent push to generate even larger libraries
through combinatorial chemistry has again set higher
throughput demands. The future may well be UHTS
which will require new robotic concepts to meet the
demands for robustness of these systems. Clearly, the
days of a single robot running up and down a single
track will soon be done. The HTS laboratory must
incorporate new technology and new automation as it
becomes available to prepare for the demands of tomor-
row as well as today. Managing this often rapid turnover
of automation requires that HTS labs always be ready to
adapt and change as needed.
Available options for doing more with less: labora-
tory automation as one tool in the arsenal
Stephen Scypinski, John Baiano and Theordore Sadlowski,
Hoffmann-La Roche Inc., Nutley, NJ, USA
As anyone involved in the pharmaceutical analysis aspect
of drug development knows, projects that require analy-
tical support can evolve from a number of different
situations, some of which include:
New molecular entities from drug discovery.
Process changes.
Packaging changes.
Site changes.
Line extensions.
Unlicensed projects and compounds.
Laboratory automation has been shown to provide a
viable and practical solution to assisting in analytical
development. However, it is not always the most logical
answer. A truly flexible and responsive analytical unit
will make a decision on a case-by-case basis, when faced
with a new project, whether it is best to:
Automate some or all aspects/testing involved.
Contract out to a reputable and approved Contract
Research Organization (CRO).
Hire temporary help.
Use available in-house resources.
Use a combination of the options above (for ex-
ample, evaluate the complexity of the new project
versus what the in-house resources are currently
working on).
In this presentation, emphasis was placed on an evalua-
tion of various situations and suggested options for the
most effective use of resources. The role of automation as
one of the important tools in the arsenal of these options
was highlighted.
Managing automation development in harmony
with the rest of an international pharmaceutical
companymA QC laboratory manager’s perspective
Paul Newton, Glaxo Wellcome Inc., Zebulon, NC, USA
Transition from managing laboratory automation devel-
opment of test methods for pharmaceutical products
within the QC laboratory at one manufacturing site to
participative management with other manufacturing and
development groups offers significant opportunities and
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challenges. Areas to consider before taking on a com-
pany-wide automation development harmonization pro-
gramme were offered. The approach that Glaxo
Wellcome is taking for international harmonization of
automation development for pharmaceutical analysis was
presented. Specific examples of automation that are
being attcted by this co-operative effort, the experiences
encountered up to this point, and potential benefits that
will be delivered were discussed.
Managing a robotics laboratory in a QC environ-
ment
Iltifat Hasan, Matt Citardi and Muhammad Alburakeh, Barr
Laboratories, Pomona, NY, USA
Managing a laboratory
fully benefit from the
robotics, it is essential
automation in general.
stand (or think they do)
often do not realize the
is difficult enough. In order to
implementation of laboratory
to understand robotics, and
While many managers under-
the benefits of automation, they
types of problems that robotic
implementations can create. Automation provides vary-
ing challenges in validation, trouble-shooting, main-
tenance, training and regulatory compliance that
cannot be overlooked. This presentation covered the
management of robotic systems, including the up-front
work necessary to properly integrate them into a Q,C
laboratory environment.
Laboratory automation--Some perspectives on
the challenges in the implementation of the tech-
nology in pharmaceutical development
Nigel North and Simon Smith, Smithkline Beecham Pharmaceu-
ticals, Harlow, Essex, UK
The intensifying pressure on reducing development time
for new pharmaceutical products is resulting in an
increasing need for laboratory automation. A key ele-
ment for the successful implementation of robotics for
product analysis is the establishment of a reliable process
for interaction of the automation team with its various
customers (for example, development product team and
manufacturing group). Major Phase 2/3 products are
targeted for robotics, these methods are used for stability
studies to support regulatory filings. The reduction of
cycle time for product development appears to be result-
ing in more stability studies to support NDA/MAA filings
for several reasons. First, key clinical information may
not be available before initiation of the stability studies
and, second, simultaneous world-wide development may
result in an increase in the number of product strength
and pack options.
Technology transfer of robotic analytical methods to
manufacturing is also more facile providing the manu-
facturing group has made the strategic decision to mirror
the robotic equipment available in the development
team. At present, few contract testing laboratories have
robotic automation available which restricts outsourcing
of large stability studies using this technology. Some
perspectives on the challenges to maximizing the benefits
of laboratory automation described above were dis-
cussed.
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Creative design and implementation of automated
microbial susceptibility testing
Chris Bierman and Theresa Kajs, Procter & Gamble, Mason,
OH, USA
Microbial susceptibility testing (MST) is a government
mandated stability indicating analysis designed to test
the efficacy of preservative systems with product ma-
trices. The analysis requires that products packaged in
MultiDose containers can be challenged with, at mini-
mum, five USP specified microbes at a specific concen-
tration. Products are subsequently plated over a 28-day
period to check for microbial recovery and are deemed
pass or fail based on the log reduction from the initial
microbial concentration in product. The analysis can be
broken down into three specific tasks:
Sample preparation and innoculation.
Sample plating.
Data collection and results dissemination.
Health Care Microbiology at Procter & Gamble worked
with Bohdan Automation to automate the sample plating
procedure of MST as written in USP XXIII. This
presentation discussed the design and validation of the
two-robot system.
Assessing climacteric
boxes of apples
ethylene of 100 million
Eric Curry, USDA/Agriculture Research Service, Wenatchee,
WA USA
The apple is a remarkable fruit. If harvested at optimum
fruit storage potential, it is not uncommon to store them
for at least 12 months under proper temperature and
atmospheric conditions. Correct timing of harvest is
predicated on defining the maturity of the apple, or stage
of ripeness, which is determined by measuring fruit
ethylene biosynthesis. Presently, the task of the apple
industry is to assess the ripening status of about 10 billion
apples in a six-week period to determine how to best
store them for optimum fruit quality. First attempts to
measure ethylene were done using bulk samples placed in
a sealable container from which a headspace sample was
taken periodically. This method was too qualitative,
because one apple could be riper than the others, thereby
generating most of the ethylene. The next attempt was to
measure ethylene from individual fruit by taking a small
sample of gas from the core with a large needle. This
method reduced error; however, the number of samples
grew prohibitively large. The method under design of
assessing individual fruit is to place each apple in a
small, 3-1itre Plexiglas chamber with a low flow of
scrubbed air. Microprocessors will allow the sampling
of effluent gas as often as required 24 hours a day. This
takes one person about h to set up the system in order to
accomplish the sampling of hundreds of apples that
manually took about 2-3 min per sample. The greater
number of samples both reduces error and increases the
likelihood that apples will be in the consumer’s hand with
optimum quality.Abstracts of papers presented at the 1997 ISLAR
Modified automated titration system equipped
with an ultrasonic homogenizer for the assay of
absorbing gel materials in diapers
Kyoko Ida, Shunji Ishigami, W. Nakagawa, Procter & Gamble
Far East Inc., Kobe, Japan
The current system for quantitative determination of
Absorbing Gel Materials (AGM) in infants’ diapers
(nappies) utilizes air bubbling in the extraction pro-
cedure followed by acid-base titration. However, two
issues have arisen. One is a corrosion problem on stainless
steel frame due to acid vapour coming from the extrac-
tion bath. The other is an increased number of samples
beyond the capacity of the current system. To overcome
this situation, we modified the system. The bath was
covered during the extraction to prevent acid vapour
diffusion and replaced air bubbling with ultrasound to
reduce the extraction time thus increasing sample hand-
ling capacity.
The system consists of a Zymate XP robot, three sample
racks (36/pads/rack), a Mettler titrator, extraction bath,
ultrasonic homogenizer, three pumps, two balances and a
waste container. It provides more than 98% recovery.
The extraction using ultrasound requires only 3min
while the current system 8 min. One extraction bath in
this new system proved superior to or at least equal to
three baths using air bubbling. In conclusion, the new
system enhanced our capability ofAGM assay and solved
the corrosion problem.
Automation of the Rose Gottlieb method for fat
determination in dairy products using an expert
system
Alan R. Matheson and Patrick Otten, Alphatech @stems,
Auckland, New Zealand
The Rose Gottlieb test is the internationally recognized
gravimetric method for the determination of fat in a wide
variety of food products. It is extensively used in the New
Zealand dairy industry for the calibration of infrared
testing equipment and for the customer acceptance test.
The hardware and software used to automate this time-
consuming and tedious assay were described. The se-
quence of operations is determined by an expert system
rather than a scheduler. The expert system regularly
queries the status of the automated equipment and then
issues appropriate commands to the robot controller,
after consulting a rule set describing the assay procedure.
This still relatively novel approach to laboratory robotics
control results in a high degree of concurrency and the
ability to adapt to incoming samples with varying assay
protocols.
Automation of multiple parallel solid phase syn-
thesis: reproducing the scope of synthetic trans-
formations on solid phase without compromise
James B. Campbell and Richard A. Wildonger, Zeneca Pharma-
ceuticals, Inc., Wilmington, DE, USA
A collaborative effort between Zymark Corporation and
Zeneca, Inc. (USA) during the past year has produced a
novel, high capability automated parallel solid phase
synthesis instrument as the central component of an
integrated workstation-based system. A fundamental
objective in the collaboration was to ensure that chem-
istry would guide the decision of the automated platform
to enable reproduction of the manual operations em-
ployed by the practicing solid phase synthesis chemist as
precisely as possible. The instrument resulting from the
collaboration has incorporated several unique fhnctional
capabilities that mirror, and to a certain extent, enhance
some of the process operations involved in solid phase
synthesis. Notable among these capabilities are three
methods of liquid reagent and solvent transfer which
can function independently or in concert. These include:
Parallel delivery and clearance (multiple channel).
Serial delivery (single channel, closed architecture).
Robotic delivery (single channel).
Other capabilities include access to broad temperature
ranges for both heating and cooling, the non-aggressive
agitation of resin, and the strict maintenance of an inert
environment. Examples of representative synthetic trans-
formations that were performed on the synthesizer were
presented and compared with manual methods of syn-
thesis. Also, advantages of the modular platform and
integration with other automated workstations were
presented.
Progress toward the implementation of an inte-
grated workstation-based multiple parallel solid
phase synthesis system
Richard A. Wildonger and James B. Campbell, Zeneca Pharma-
ceuticals, Inc., Wilmington, DE, USA
In response to the burgeoning advances in the high
throughput synthesis arena, and in consideration of our
requirements, we sought to acquire, or develop a work-
station-based synthesis system that would meet our
current needs in supporting solid phase parallel synthesis
and would be amenable to modification and expansion to
meet future needs. Thus, we set out to automate selected
sub-processes associated with multiple parallel solid
phase synthesis. These sub-processes included diversity
reagent preparation, synthesis (reagent addition, mixing,
and washing), off-line incubation and product cleavage.
As the heart of the system, the synthesis workstation
required ambitious specifications in order to be able to
accommodate the broad range of chemistry we wished to
investigate. We fully recognized that with these high
expectations, we had defined an exceedingly complex
instrument.
Against these criteria, no currently available commercial
product measured up to our expectations or require-
ments. Therefore, a collaborative effort between Zymark
Corporation and Zeneca Pharmaceuticals (USA) was
established to develop an instrument. In this collabora-
tion we were guided by the belief that the chemistry
should define the automated platform rather than trying
to adapt the chemistry to an existing platform. During
the past 18 months a high capability automated MPS
synthesis instrument that incorporates features of both
plumbed/valved and robotic machines has been pro-
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duced. This instrument is unique in that it exemplifies
three modes of reagent addition, namely plumbed-serial
and plumbed-parallel, and robotic-serial. Furthermore,
spent reagents, impurities and soluble byproducts are
removed by filtration using positive pressure differentials
rather than vacuum thus avoiding atmospheric contam-
ination. Additional features of this instrument were
discussed and details of its performance to date provided.
Progress toward implementing the other workstations in
this system was outlined and some directions for future
system expansion were proposed.
Evolutionary design of a combinatorial chemistry
system for late stage lead optimization
Harold 2V. Weller, Bristol-Myers Squibb Pharmaceutical Re-
search Institute, Princeton, NJ, USA
Combinatorial chemistry has proven to be a powerful
tool for lead generation in drug discovery programmes.
Application of automated synthesis methods to later
stages of lead optimization has received less attention,
largely due to the diculties associated with character-
ization and purification of large numbers of samples. This
presentation described the evolution of a combinatorial
synthesis system designed for lead to optimization in the
late stages of drug discovery programmes, including
modules for synthesis, analysis and purification. Evolu-
tion of these modules in an environment where the need
to produce new compounds immediately is balanced
against the need to develop optimal automated pro-
cedures was described.
Process integration of automated synthesis sta-
tions: ’gluing’ the parts together
Michael Routburg, A1 Washington and Je Pan, Abbott
Laboratories, Abbott Park, IL, USA
In the development of automated systems for parallel
synthesis, the glue that is necessary to piece together the
separately automated tasks into an integrated process has
both hardware and software components. The following
list, while not complete, represents the bulk of the
required interfacing.
Hardware glue components:
Changing the product from liquid to dry state, and
back again.
Transferring the product from one vessel to another.
Distributing accurate portions of the product from
one container to another.
Identifying the containers.
Software glue components
Tracking single samples and/or purified fractions.
Combining selected samples into groups for ease of
processing.
Identifying and accounting for exceptions (for ex-
ample, insolubles, dual tube fractions, and by prod-
ucts of the reaction unrelated to the desired
product).
Monitoring the process.
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Archiving data to a central data repository.
These hardware and software components are solution
independent, and will most likely need to be addressed in
any parallel synthesis automated system integration
regardless of the format of the automation being inte-
grated. This paper discussed the various parts of the glue,
and then addressed the approach Abbott used for the
software and hardware integration of the overall auto-
mation.
Robotic solid phase extraction and GC/MS analy-
sis of THC in blood
William Stonebraker, State of Utah, Department of Health, Salt
Lake City, Utah, USA
The ever-increasing number of DUI arrests worldwide
necessitates an accurate, sensitive and easily automated
analytical method for analysing THC (tetrahydrocanna-
binol) in the blood of marijuana smokers. The method
developed by our laboratory utilized Zymark Rapid-
Trace Robotics and SPE (solid phase extraction) to
extract the THC and THC-COOH from blood samples
submitted by law enforcement agencies in DUI arrests.
After extraction, the samples are derivatized with TFAA
(trifluoroacetic anhydride) and then analysed using a
VG Instruments Trio-1 GC/MS equipped with NCI/
SIM (negative chemical ionization with single ion mon-
itoring). The molecular ions of the two compounds are
monitored in this analysis, and a deuterated internal
standard is added for quantitation.
The method is based on a manual method that has been
performed for several years by the laboratory and allows
a maximum of 60 samples per run. The limit of detection
(LOD) is equal to or superior to the manual method. The
analysis requires approximately one half the time necess-
ary for the manual method from the beginning of sample
preparation through extraction/derivatization and GC/
MS data reduction to the final report.
Application of a BenchMate
TM biological monitor-
ing method for the chlorophenoxy acid herbicides
24D, dicamba, dichlorprop, 245TP, 245T, and 24db
in urine
Ken Brown, C. A. Striley, C. D. Lorberau, and C. J. Hines,
National Institute for Occupational Safety and Health, Cinci-
natti, OH, USA
A poster entitled ’BenchMateTM assisted chlorophenoxy
acid herbicides urianalysis method for biological mon-
itoring of exposed field applicators’ was presented at
ISLAR ’96. This poster described a method developed
around the use of an automated workstation. Most of the
analytical methods developed in our laboratory are for
small batch sizes of novel analytes, which are not
commercially available. Was this type of laboratory
automation amenable to our laboratory? How did the
method perform? What were some of the maintenance
and repair issues encountered during the study? Did
automation reduce the handling of urine and toxic
reagents and analyst stress resulting from monotonous
repetitive tasks?Abstracts of papers presented at the 1997 ISLAR
Since the initial presentation, this method has been
applied to two sets of human urine samples, N 50
and N 600. For processing, each analysis batch con-
tained 30 samples; this included eight calibration urines,
three QC urines, one interbatch split, one intrabatch
split, two blank waters and one spiked water. This high
percentage of quality control samples left room for only
17 field samples per batch. However, tracking the quality
control samples over this study allowed us to characterize
this method for accuracy, precision, carryover, and
sample throughput. The performance of the Bench-
MateTM Workstation, HP 6890 Gas Chromatograph,
and the method was monitored during the analysis of
these samples.
The BenchMate
TM performance was monitored by
tracking the output.dat file from each batch which
contained a mass audit record of each sample prepara-
tion step. For each mechanical step out of control,
concurrent repair and maintenance logs were examined.
The performance of the GC instrument was monitored
using an internal instrument performance standard
(IIPS) in each sample. The IIPS added after sample
preparation to the extract was used for the determination
of chromatographic efficiency, retention time, and sensi-
tivity (mV/ng) for each sample. An internal standard
(IS) added to the derivatization efficiency and precision.
Method performance was also characterized for each
batch by monitoring blank water, spike water, QC urine,
interbatch split field, and intrabatch split field sample
analyses.
In order to more fully evaluate this automated GC
procedure, samples were assayed using other analytical
methods for comparison. One batch of samples was
simultaneously analysed by an automated immunoassay
method and another batch by isotopic dilution high
resolution MS using C13 24D and deuterated dicamba.
In summary, the BenchMate procedure was precise and
sensitive. It also reduced sample handling by the analyst
and compared favourably with results of other analytical
methods. These results suggest that the automated pro-
cedure is the method of choice for unique biological
monitoring methods.
A versatile, open-access, high-throughput micro-
plate format bioanalytical robotics system
Glenn A. Smith, Jimmy Brunet, John R. Alianti, GlaxoWell-
come Inc., Research Triangle Park, NC, USA
Recent advances in automation, programming and
microplate formatted bioanalyses have facilitated the
implementation of novel bioanalytical robotics systems.
These latest systems combine the main advantages of
traditional robotics systems (i.e. versatility and fully
automated assays) and workstations (i.e. ease of use,
reliability and productivity), as well as offering a few
new advantages:
Each system can support the link multiple applica-
tions without reconfiguration or additional pro-
gramming. Furthermore, the systems have been
created to support not one but most types of bio-
analytical extraction techniques in a 96-well format.
These include ultrafiltration, protein preciptation,
liquid/liquid and solid phase extractions.
Custom Visual Basic software allows the users, even
those with little or no Zymark and/or Tecan experi-
ence, to intuitively set up a new application or select
and run a previously created application. The soft-
ware allows the user to define, automatically link
and subsequently execute their assay, even when
the system is actively running another application.
The systems are each comprised of a Zymate XP robot, a
Tecan RSP 8051 liquid handling system for the transfer
of samples, a reagent addition station (RAS) equipped
with dual 12-port solvent selection valves for all liquid
additions, a microplate vortex station, a 96-well evapora-
tion station, a Sagian plate sealer, a temperature con-
trolled carousel for the storage of all microplates and
extraction devices (i.e. SPE blocks and filtration plates),
and most importantly, a custom microplate centrifuge
which serves as an extraction station for all supported
applications.
Advances in membrane SPE for high throughput
pharmaceutical bioanalysis
David Wells and Li Song, 3M I&C Sector Research &
Development, St Paul, MAY, USA
Applications of membrane and solid phase extraction in
96-well microtiter plate format were presented for the
analysis of drugs in biological fluids. The 96-well plates
contain particle loaded membranes which are composed
of chromatographic particles tightly held together within
an inert polytetrafluorethylene (PTFE) matrix (90%
particles: 10% PTFE, by weight). The membrane SPE
technology, as a result of its small bed volume, allows
analyte elution in a very small solvent volume (compared
when processed with small volumes of mobile phase
compatible solution). The injection can be made out
the very same collection plate when configured with an
extraction method, together with elimination of the
eluate evaporation step, to contribute to fast processing
times. The processing speed complements the high
throughput conventional LC/MS analysis. Automation
of the extraction method is accomplished by a variety of
liquid handling workstations which are programmable
and offer semi-automated processing of 96-wells’ plates.
Each of these automation options was presented in detail.
The automated membrane SPE system provides the
solution to the sample preparation bottleneck now facing
bioanalytical chemists.
Development and validation of an automated
method for the analysis of 3,3’,4,4’-pentachloro-
biphenyl (PCB-126) and 2,3,4,7,8-pentachlorodiben-
zofuran (4-PeCDF) in rat tissues
Ed Psurny, B. Harritos, K. Carrico, B. Burback, J. White and
S. W. Graves, Battelle Memorial Institute, Columbus, OH and
C. S. Smith, National Institute ofEnvironmental Health Services,
Research Triangle Park, NC, USA
An automated method has been developed, validated
and used for the analysis of PCB-126 and 4-PeCDF in
37Abstracts of papers presented at the 1997 ISLAR
serum, fat, lung and liver tissues from Harlan Sprague
Dawley rats utilizing the Zymark BenchMateTM Work-
station and gas chromatography/high resolution/mass
spectrometry (GC/HR/MS). The method was developed
for the National Toxicology Program’s Toxicology
Equivalence Factor Dioxin Initiative (TEFDI). The
large number of samples expected to complete TEFDI
required a method that was rugged, precise, efficient and
cost effective. Most current methods in the literature are
cost, labour and time intensive. Therefore, a method
utilizing automated solid phase extraction was developed
for these compounds. The final 4-PeCDF tissue cleanup
consisted of saponification, hexane extraction, and auto-
mated solid phase extraction using a silica gel cartridge
followed by a florisil cartridge. The final PCB-126 tissue
cleanup consisted of saponification, hexane extraction,
and automated solid phase extraction using silica gel and
activated carbon cartridges. Samples are then analysed
by GC/HR/MS. The range of the assay is from 5 to
1000 pg/g. Over 1500 toxicokinetic study samples have
been analysed by these methods to date.
A high throughput analysis of a novel drug candi-
date in human plasma using a fully automated on-
line sample preparation system
L. Lin, J. Y.-K. Hsieh, B. K. Mat,szewski, and M. R.
Dobrinska, Merck Research Laboratories, West Point, PA, USA
Automation of sample preparation and analysis not only
increases sample throughput but also reduces sample
turnaround times. It is the most cost-effective way to
meet the demanding objective of the ever-increasing
workload faced by bioanalytical laboratories today. Full
automation, in which the entire analytical procedure
from sample preparation, extraction, data analysis to
report generation is automated, has been the ultimate
goal of many laboratories. Recent advances in the design
of laboratory automation equipment provide powerful
and flexible means for achieving full automation. This
paper described a high performance liquid chromato-
graphic (HPLC) system coupled with a fully automated
solid phase extraction (PROSPEKT4)) unit, a fluores-
cence detector, and a data processing system. The solid
phase extraction tasks performed by the PROSPEKT
unit include on-line sample loading, cartridge condition-
ing, cartridge washing, analytes eluting, HPLC injection,
data analysis, and report generation. A selected applica-
tion (quantification of a novel drug candidate in human
plasma) was used to illustrate the performance and
benefits of this fully automated system. Validation and
stability data from the analysis of spiked and subject
plasma samples were also presented.
LC-MS/MS method for the analysis of salbutamol
in human plasma and urine using automated solid
phase extraction (SPE) for sample preparation
T. Sauter, J. Schmid and D. Schetze, Boehringer Ingelheim
Pharma Deutschland, Biberach an der Riss, Germany
A sensitive method for the analysis of the 132-agonist
salbutamol in human plasma and urine was developed
and validated. After addition of the internal standards
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I2H9] salbutamol, salbutamol was extracted from plasma
or buffered urine by. automated SPE procedures on a
Zymark RapidTrace
TM Workstation. Chromatography
was achieved on an analytical C18-HPLC column with
gradient elution. Salbutamol was quantified by MS/MS
with electrospray ionization.
The salbutamol sulphate metabolite was separated from
the salbutamol by chromatography (plasma) or the SPE
procedure (urine). The calibration curves of undiluted
samples were linear over the range of 15.0-4000 pg/ml for
plasma and 0.250-100ng/ml for urine. Assay validation
sample measurements showed inaccuracies of the quality
control samples of 2.8-0.4% for plasma and 2.4-6.4% for
urine. Maximum assay imprecisions were 5.9 and 5.4%
for plasma and urine samples, respectively.
Maximum carry-over effects obtained in the chromato-
graphic system were in the range of 0.3%. Carry-over
effects in the RapidTrace
TM Workstation measured after
preparation of samples spiked with 100 ng salbutamol/ml
urine were below 0.1%. The total recovery after auto-
mated SPE was 79.1-81.6% in the concentration range
of 100-1200pg salbutamol/ml plasma. For urine, it was
70.5% and 62.1% at concentrations of 2.00 and 100 ng
salbutamol/ml, respectively. The method was successfully
applied for the analysis of about 3000 samples from
clinical trials.
Development and routine bioanalysis of a novel
drug substance using automated 96-well solid
phase extraction and LC-MS-MS
S. R. Bessant and D. R. Lachno, Lilly Research Centre,
Windlesham, Surrey, UK
A rapid, robust and sensitive method was required to
routinely determine levels of a novel drug substance in
human plasma to support early phase clinical trials. A
Canberra Packard Multiprobe pipetting robot with SPE
functionality was the instrumentation of choice for both
method development and routine analysis. Preliminary
work identified 3M Empore
TM discs as the most suitable
extraction medium with 96-well capabilities and the 3M
vacuum manifold gave greatest vacuum efficiency.
Initial development problems included carry-over be-
tween wells, inconsistent extraction across the plate and
blocked wells. These issues, once identified, were rela-
tively easy to overcome with simple adjustments to the
extraction procedure and the vacuum pump used. The
method was completed by development of an LC-MS-
MS assay which enabled rapid analysis of extracts using a
Sciex API III + instrument in the multiple reaction
monitoring mode using a deuterated analogue of the
drug substance as the internal standard.
The most obvious advantage of this method is speed
where a number of factors are contributory. SPE using
the 96-well format on the Multiprobe and the speed of
the LC-MS-MS analysis are obvious time-savings but
additional time is saved by the reduction in sample
handling and pipetting. Data quality is also improved
as the chances of human error and inconsistencies are
reduced, making this method not only more efficient inAbstracts of papers presented at the 1997 ISLAR
the originating laboratory but more compatible with
method transfers.
An efficient solid phase extraction of a novel drug
candidate from plasma using Empore
TM disks in a
96-well format and application of the method for
assaying samples from human pharmacokinetic
studies
R. S. Mazenko, E. J. Wolf, J. Hsieh, B. Matuszewski, Merck
Research Laboratories, West Point, PA, USA
Our laboratory is investigating a variety of methods to
increase the throughput of clinical sample analyses. As
part of this effort, the applicability of using Empore
TM
disks configured in a 96-well format for the extraction of a
novel drug candidate from human plasma samples was
evaluated. The sample preparation portion of a previous
developed method for the determination of a proprietary
non-polar drug candidate in human plasma using HPLC
and fluorescence detection was successfully modified to
use the extraction plates rather than conventional indi-
vidual solid phase extraction (SPE) columns. The ability
to elute the analytes of interest from the extraction plate
with a small volume of solvent was found to eliminate the
need to evaporate extracts and reconstitute the samples
prior to analysis. Consequently, sample throughput could
be increased by 50% as compared to the conventional
solid phase extraction procedure. The modified assay was
validated over the concentration range of 5 to 400 ng/ml.
Replicate analyses (n 5) of spiked plasma standards
from 5 to 400 ng/ml yielded coefficients of variation less
than 2.3%, and accuracies within 3% of the nominal
concentrations. Details regarding the conversion of the
assay to the 96-well format were presented. The method
was successfully applied to the analysis of plasma samples
tiom several pharmacokinetic studies. Additionally, the
applicability of using an automated liquid handling
station to perform the extraction of clinical samples with
the Empore
TM plate was described.
An integrated information system for drug dis-
position data
Wade J. Adams, Paul A. Bombardt, John D. I-Iosley, Kathleen
S. Chapman, Donald P. Dame, Chau 1t. Mai, Nancy J.
DeBliek, Chris J. Glass, Dianne C. Hollenbeck, Phillip M.
Stmdman and Dean W. Knuth, Pharmacia & Upjohn, Inc.,
Kalamazoo, MI, USA
An integrated information system has been developed by
Pharmacia & Upjohn, Inc., for the interactive analysis of
the large amounts of data typically generated in single-
and multiple-dose drug disposition studies. The system
utilizes IBM PC compatible workstations in conjunction
with a Harris NH4402 super minicomputer and PENel-
son 900 series chromatographic interfaces for real-time
acquisition and processing of chromatographic data, in-
house developed software for importing chromatographic
data from remote research facilities electronically using a
standardized data format, an IBM 310 P133 server for
acquisition, processing and storage and analytical bal-
ance and scintillation counter data using the commer-
cially available DEBRA System (Version 4.2, LabLogic
System, Sheffield, UK), and an IBM 3090 mainframe
computer for protocol specific integration, storage, phar-
macokinetic and statistical analyses, and archival of data.
Chromatographic data from automated gas and liquid
chromatographs equipped with a variety of detectors,
including mass spectrometers, are acquired on the Harris
NH4402 and processed to calculate drug/metabolite
concentrations for quality controls and unknowns from
standards data using the in-house developed UPACS
Chromatography System. Following evaluation of data
for chromatographic run, standards, controls and un-
knowns data are transferred electronically from the
UPACS Chromatography System or from remote re-
search facilities to the in-house developed ADME System
resident on the IBM 3090 using standardized formats.
The data are stored by study protocol in an SQ,L/DS
data base. Raw data for each UPACS Chromatography
System analytical run can then be achieved on the Harris
NH4402, and the data from remote research facilities can
be retained on the IBM 3090.
In a similar manner, drug dose, body weight and drug
equivalents data are transferred electronically from the
DEBRA System to the ADME System following evalua-
tion of the data for each run. The raw data can then be
archived on the IBM 310 system. The ADME System
can be used to edit the integrated data for a protocol,
calculate preliminary pharmacokinetic parameters, gen-
erate tabular reports and plots, and allows the user to
selectively extract and transfer data using standardized
formats for more extensive pharmacokinetic and statis-
tical analyses of the data or the preparation of user-
customized reports. This integrated information system
increases the reliability of data by eliminating data
transcription, provides audit trails of edited data, and
greatly reduces the time and effort necessary to analyse
and report data from single- and multiple-dose drug
disposition studies. In addition, the system is GLP
compliant.
PhASSETS (R), an automated extraction system for
fast method development and production in analy-
sis of trace levels of drugs in biological fluids
Carl Dourambeis, Rene Michaud, Daniel Dorval and John
Burrows, Phoenix International Life Sciences, Inc., Montreal,
Canada
PhASSETS (R) (Phonenix Automated Simple Sample Ex-
traction Treatment System) is a novel technology, devel-
oped at Phoenix International used to extract trace levels
of drugs from biological fluids. The PhASSETS (R) system
includes a proprietary, pretreatment, multilayer, extrac-
tion cartridge accompanied by a robotic processor. This
system allows the development chemist the ability to
perform multiple extractions in a single pilot run.
PhASSETS (R) uses thin-film liquid/liquid theory. Up to
four extraction solvents, four internal standard ana-
logues, and a variety of specially prepared cartridges
may be used together to quickly develop methods.
Manual methods in comparison, may take up to two
weeks to obtain the same results obtained by one
PhASSETS (R) pilot run. Key features of this bioanalytical
extraction system include the ability to extract large
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volumes of samples to be used in various detection
laboratories (HPLC, GC, GC/MS, LC/MS, etc.).
Through key examples, the method development tech-
nique used with PhASSETS (R) as well as the scope of the
applicability of this novel system was presented.
High throughput extraction of basic and polar
drug compounds from biological matrices with a
novel polymeric solid-phase sorbent in a 96-well
format
Judy L. Carmody, Yung-Fong Cheng, Dorothy Phillips, Pamela
baneta and Uwe Neue, Waters Corporation, Milford, MA,
USA
Historically, sample preparation has been the bottleneck
in laboratory productivity, especially with the onslaught
of LC/MS/MS. Rapid and reproducible quantitation of
classically difficult, basic and polar drug compounds from
biological matrices has, in the past, been a challenging,
time-consuming endeavour. Necessary sample prepara-
tion techniques used to concentrate or clean-up matrices
before HPLC, GC or LC/MS analysis of basic com-
pounds have proven to be either tedious and labour
intensive or irreproducible. Presently, the most com-
monly used technique for high throughput sample
preparation is reversed-phase solid phase extraction in a
96-well format. The sorbent generally utilized is porous
silica surface-bonded with Cla. The major disadvantage
to employing this type of system with basic compounds is
that the silanols on the silica surface can deleteriously
affect the recovery of the basic compounds. The surface
silanols interact through ion exchange with basic com-
pounds, such as Doxepin. This interaction prevents
complete elution of basic compounds and results in low,
variable results. With polar compounds, such as Procain-
amide and Ranitidine, the analyte/sorbent interaction is
low resulting in breakthrough of the polar analyte. This
subsequently, yields poor, irreproducible recoveries. An-
other notable disadvantage to using traditional silica-
based reversed-phase sorbents is that the wettability must
be maintained through the tedious manipulation of stop-
cocks. The capacity of C18 is severely compromised if the
sorbent runs dry.
This paper showed how the sample preparation bottleneck
has been eliminated. Highly reproducible and uncompli-
cated SPE methods were developed for these types of
basic and polar drug compounds using a novel polymeric
TM solid-phase sorbent, Oasis HLB, in a 96-well format.
Recoveries greater than 90% and reproducibility less
than 5% RSD (n 96) for basic antidepressant and
polar drugs were realized. Most importantly, because
Oasis
TM HLB is a water wettable polymer, these results
were achieved without concern as to whether or not the
sorbent ran dry.
The robotic manufacture of a non-disintegrating
polymeric capsule for controlled release applica-
tions
A. R. DegVoto and A. G. Thombre, Pfizer, Inc., Groton, CT,
USA
A robotic process was developed to manufacture non-
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disintegrating polymer capsules for controlled release
applications. The capsules were made by a phase inver-
sion process--the membrane structure was precipitated
on a mold pin by dipping it in a coating solution followed
by quenching. The coating solution was a polymer-
solvent-nonsolvent system that yielded an asymmetric
membrane wall, i.e. a wall composed of a thin dense
region supported by a thicker porous region. The final
dosage form was assembled by filling the capsule with a
drug-excipient mixture and then sealing the seam of the
capsule body and cap.
A Zymate II robotic system (Zymark Corporation,
Hopkinton, MA) was programmed to perform the unit
operations of dipping, withdrawing, spinning, quenching
and drying the capsules. The manufacturing set-up
consisted of the robot at the centre and the following
elements arranged in a circular fashion within the reach
of the customized robot-arm:
A line-feed for the fixtures with mold pins.
The dip-bath for the coating solution with a pneu-
matically operated cover.
The quench bath capable of holding a maximum of
30 fixtures.
A blower to get rid of any excess liquid remaining
on the capsules.
Drying rails.
The robot was programmed to sequentially process six
dip fixtures. The robot arm picked up a dip fixture from
the line feed and positioned it above the dip solution
tank. The pneumatically operated cover was automati-
cally opened and the dip fixture was plunged slowly into
the coating solution and withdrawn over 12s. After
withdrawal, the fixture was rotated twice in opposing
360 turns. It was then moved to the quench solution
bath. This cycle was repeated with the remaining dip
fixtures. After 15 min in the quench bath, the robot was
programmed to transport each of the fixtures over a 10
air blast and park them on rails for a 30 min drying step.
The fixtures were then removed from the rails from the
manual stripping, trimming, and joining operations.
The robotic process was versatile which proved extremely
useful during the process development and optimization
stage. Capsules of consistent quality were manufactured
in quantities typically required for formulation develop-
ment and for providing supplies for clinical, toxicity, and
stability testing.
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A Bohdan automated workstation for microbial
identification sample preparation
Martha H. McDaniel, Nancy J. Hodges, Robert L. Dinkel,
Robert L. Ellington, and Michael L. Rutherford, Eli Lilly and
Company, Indianapolis, IN, USA
In the last several years, regulatory agencies’ expecta-
tions for environmental monitoring have increased dra-
matically, not just for parenteral operations, but for all
pharmaceutical manufacturing operations. As a result,Abstracts of papers presented at the 1997 ISLAR
there is an increased need for microbial identification.
Classical microbiological techniques, such as the API
System and bioMerieux Vitek System, have been used
for years to identify various microorganisms. However,
these techniques can be very time-consuming and/or
expensive, and do not provide the high throughput
capabilities necessary to meet the growing demands for
microbial identification. Several newer alternatives have
been developed which can address the lower cost and
potential higher throughput needs, such as the Microbial
Identification System (MIS) Whole Cell Fatty Acid
Analysis by Gas Chromatography by MIDI. This tech-
nique uses peak naming and pattern recognition algor-
ithms to identify fatty acid extracts of microorganisms
processed on a Hewlett-Packard gas chromatograph. The
preparation of the extracts is divided into five basic steps:
harvesting, saponification, methylation, extraction, and
washing. The latter four steps require various sample
processes including the addition of reagents, vortexing
and mixing, heating and cooling, and liquid phase
extraction. Consequently, this extraction process can be
rather tedious and labour intensive, especially in a high
volume situation.
In order to meet an increased need for sample capacity,
the authors worked with Bohdan Automation, Inc., to
develop a compact benchtop automated workstation to
perform the saponification, methylation, extraction, and
washing steps of the microbial sample extraction.
Through the adaptation of novel combinatorial chemis-
try/reaction block approaches to switch from slower serial
to more efficient batch modes of operations, it was
possible to automate this sample preparation. A descrip-
tion of the assay methodology along with the workstation
components, features, and capabilities was presented.
Comparison data for the automated versus manual
methods was also presented.
A Gilson 215 multi-probe liquid handler: a versa-
tile system for under $26 000
Terry L. Stinger and Michael L. Rutherford, Eli Lilly and
Company, Indianapolis, IN, USA
Since its introduction several years ago, the Gilson 215
Liquid Handler has proven itself to be a versatile, large
capacity, septum-piercing liquid handler for fast, safe,
and efficient sample preparation and transfer. This XYZ
robotic system can be easily programmed to automate
any number of liquid handling procedures, including
combinatorial chemistry, RIA or ELISA bioassays,
colorimetric assays, quality control testing, autoloading
of NMR tubes, automated compound distribution
studies, serum transfer and dilution, and sample prepara-
tion and injection to HPLC. Another added benefit is the
215 Liquid Handler’s ability to pierce VACUTAI-
NERTM tubes and other equivalent thick septas, an
option not available on other economically priced liquid
handlers. The 215 Liquid Handler’s open architecture
and graphical tray editor allow for a wide variety of racks
and vessels ranging from microplates to test tubes to
125 ml bottles. With the emergence of high throughput
screening methodology and the increased use of micro-
plates for analyses, the speed and throughput of a single-
probe liquid handler can quickly become a limitation,
despite a low cost. Several multi-probe liquid handlers
are available today, but the higher cost for these systems
are more difficult to justify, especially for laboratories
with low sample volumes and limited resources. For this
reason, the authors worked with Gilson to redesign their
single-probe 215 Liquid Handler to provide multi-probe
capability, while maintaining the economical price. As a
result of this collaborative effort, this Gilson 215 Multi-
Probe Liquid Handler with up to eight probes is now
commercially available for under $26 000.
A description of the components, features, capabilities
and hardware limitations of the Gilson 215 Multi-Probe
Liquid Handler was presented. Several applications were
described to demonstrate the versatility, programmabil-
ity, and benefits of this low cost multi-probe liquid
handler.
Automation of the sterility test
Vanni Visinoni, FKV, Sorisole (BG), Italy
The norms regulating the execution of the Sterility Test
are under revision, but it is expected that the incubation
time will increase to 14 days and the retest opportunity
will be reduced. The cost of secondary contaminations
(false positive) is going to impact drastically on the
balance of a pharmaceutical company, not only because
of the value of the rejected product, but also as loss of
image, the need to modify the production schedule, etc.
Since 90% of the false positives are generated by the
operator, a reduction of these cases could be achieved by
the use of a sterile robot performing the test inside a clean
room. This approach will also allow a reduction of the
time spent by the operator inside a difficult environment
like the clean room.
An automated system is now available, based on the use
of a modified Steritest Kit, engineered by Millipore and
on a robotic arm provided by Zymark Corporation. The
automated system allows the execution of up to 40
batches in a single run for a duration of around 20h.
Only 30min of the operator’s time is required at the
beginning and at the end of the run to load and unload
the samples and the kits. The automated system is
capable of handling different types of containers like vials
(from 5 ml to 100 ml), ampoules (from 2 ml to 100 ml) or
prefilled syringes. Samples may be of different types, like
powders, liquids, bulk materials or lyophilized products.
The system has been designed to allow easy decontamin-
ation as well as easy removal of all the components
requiring sterilization.
Automated methods development and optimiza-
tion of a compound in medicated feed blends using
a Zymark Pytechnology system
L. C. J. Erhart, Pfizer, Inc., Groton, CT, USA
An overview of the automated process was highlighted
from a liquid chromatography (LC) perspective. The
process was sequentially outlined showing the develop-
ment of an analytical extraction method of a drug
analyte from feed matrix. Solubility of the drug substance
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and polarity index of the extraction solvent is utilized to
optimize resolution. The extraction efficiency is max-
imized to obtain 100% recovery with reduction of
interferences to little or none. Assay development time
is reduced by 50%. Utilizing a 486 PC, Windows, VBX
Visual Basic, Easylink, DDE and Excel, a Zymark XP
robot adds extraction solvent via a nine port valve and
extracts the drug component. The sample is transferred
to a BenchMate II Workstation for dilution, mixing and
filtration. The final extract is transferred to an EasyFill
via filling station prior to LC injection.
Application of robotic dissolution of a tablet for-
mulation to meet aggressive timelines for labora-
tory certification in support of key investigational
batches
Chrone Chert and 2Vita gatel, Pfizer Inc., Brooklyn, 2VT, USA
Dissolution has become an essential test in the control
laboratory certification programme for getting ready to
support dosage form manufacturing in an international
pharmaceutical environment. The use of a Zymate XP
robot in the dissolution testing of a tablet formulation has
addressed the laboratory certification schedule, labour
demand, and occupational exposure posed by this poten-
tially hazardous new drug product candidate. This
robotic application demonstrates how automation can
help meet business needs, achieving fast results and
ensuring personnel safety.
A robotic method for dose delivery assay for a
beclomethasone dipropionate MDI
M. O’Kane and S. Li, Schering-Plough Pharmaceuticals, Kenil-
worth, ./VJ, USA
A robotic dose delivery assay method has been developed
for a beclomethasone dipropionate MDI. The procedure
uses a Zymark robot designed to test metered dose
inhalation products. The robot system was first validated
to ensure that the robot would execute the program as
expected. Then, the validation of the dose delivery assay
procedure was performed. There were two primary
phases of procedure validation. In the first phase, the
robot was optimized to perform the dose delivery assay.
This included the efficient rinsing of the collection vessel
used to collect the samples, finding a suitable pressure to
be applied to the plungers used to actuate the sample
cans, and performing a primary study to determine the
number of times a sample can needed to be actuated by
the robot prior to sample collection. In the second phase,
it was demonstrated that the robot was able to generate
sample data comparable to sample data obtained using
the manual procedure. The robot has the capability of
assaying 45 aerosol cans. Up to a maximum of 150 vials
of sample solution can be prepared for HPLC analysis.
DMP 266 capsules: validation of
methods using Zymark WorkStations
automated
j. A. Short, The DuPont Merck Pharmaceutical Company,
Wilmington, DE, USA
DMP 266 is a non-nucleoside reverse transcriptase in-
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hibitor under development at DuPont Merck Pharma-
ceutical Company and is currently in clinical trials. Due
to the number of strengths being developed and the large
volume of release and stability testing required to support
activities to NDA, automated sample preparation
methods for assay, degradation products and content
uniformity were developed.
The drug is formulated in capsules which presented
unique challenges to our automation procedure using
the WorkStation. The method and equipment problems
were resolved and validation of the automated methods is
now complete. The technical challenges which were
overcome were discussed, and the validation results were
presented.
Modular approach to automation in a laboratory
supporting dentifrice product development
Robert E. Barton, Procter and Gamble Health Care Research
Center, Mason, OH, USA
Product development requires a different type of analy-
tical support than does manufacturing. In a manufactur-
ing setting, there is typically a limited number ofmethods
run on a large volume of samples. In a product develop-
ment setting, there is usually a much larger number of
methods and mostly small to medium numbers ofsamples
to run at any one time. The approach to automation in
these two situations is also different. Large, high-
throughput, do-it-all systems usually make sense in a
manufacturing setting, whereas in a product develop-
ment environment, they often don’t fit. Therefore, we
have taken the approach of using modular automation to
automate the work processes which make sense rather
than automating everything for automation’s sake. We
have also attempted to maintain the appropriate scale of
automation for different analyses based on sample
volume. An additional complicating factor when working
with dentifrice is the fact that it is a thick, adhesive
product with roughly 20% suspended solids. This makes
sample preparation more difficult and automation hard-
ware more complex than for many other sample types.
Descriptions of the workstations employed in our work as
well as an outline of our strategy were provided.
Validation of a newly designed automated dissolu-
tion system
Ralph Scimeca, Patrick Drumm and Douglas Judge, Novartis
Pharmaceuticals, East Hanover, 2VJ, USA
The validation of any computerized system is crucial for
any application in a good manufacturing practice
(GMP) environment. Unfortunately, this validation ef-
fort has become much more burdensome with today’s
complex automated systems. However, with the applica-
tion of targeted challenges and quality vendor IQ]OQ]
PQ documents, a high level of analytical confidence with
a minimum of effort can be achieved. Using this ap-
proach, we have validated the newly designed automated
dissolution module (ADM). This automated system is a
bathless, single vessel, dissolution unit capable of sequen-
tially testing tablets or capsules using USP apparatus 1.Abstracts of papers presented at the 1997 ISLAR
The presentation explained the ADM processes and the
authors’ approach to system validation.
Demonstrating equivalency: three essential prin-
ciples in automated method validation
Douglas Judge and Patrick Drumm, dVovartis, East Hanover,
v7,s
Automation in analytical laboratories is capable of
improving productivity levels, increasing the precision
and accuracy of results, and providing greater GMP/
GLP compliance. However, to obtain these benefits, the
equivalency between the automated and manual
methods must be demonstrated. Three important con-
siderations in assuring equivalence are:
Eective experimental design: Many subtle differences
may exist between automated and manual methods;
however, a well designed experimental plan will
identify and account for these effects.
Rigorous statistical treatment: Proper mathematical
analysis is essential to interpret analytical data
and reach defensible conclusions
Rational acceptance criteria: The evaluation criteria for
the automated processes must be justifiable when
compared to the validated manual procedures and
the testing requirements.
This presentation explained how these principles should
be applied as an essential part of the validation of
automated methods.
Automation of sample processing for NEMA-
CUR residues in groundwater and soil
Shelley L. Widmer and Gregory C. Mattern, Bayer Corporation,
Stilwell, Kansas, USA
The Environmental Fate Team at Bayer Corporation,
Agriculture Division is responsible for the development of
pesticide residue methods and the analysis of thousands of
soil and water samples annually. In order to meet the
demands of shortened development time and the large
number of samples, several Zymark Robotics systems
were designed to process both soil and water samples
from field studies required by regulatory agencies for
registration of our products.
NEMACUR9 is a non-fumigant chemical with systemic
and contact nematicidal properties. This product is
currently registered for use in the United States fbr the
effective control of nemetaodes in certain field, fruit and
vegetable crops, ornamentals, nursery stock, and turf-
grasses.
Two automated analytical methods have been developed
to process soil and groundwater samples containing
NEMACUR (R) and its degradates using Zymark robotics
systems. Custom RapidTrace workstations, designed to
handle large volume samples, use solid-phase extraction
to extract the active ingredient and degradates from
sample matrixes. A Zymate XP robot is used in conjunc-
tion with the RapidTrace workstations to complete the
processing. The final products are ml sample extracts in
autosampler vials, which are available for HPLC/MS/
MS or HPLC analysis.
Development of an automated solubilization
method for quantitation of radioactivity in tissues
K. Gibson, M. Dryzga, J. Ormand and C. Thornton, The Dow
Chemical Company, Midland, MI, USA
The Health and Environmental Research Laboratory
generates kinetic, metabolism and mechanistic toxicity
data that are required for product registration, and
provides important insight on chemical toxicity. Quali-
tative and quantitative assessment of metabolism is
determined by processing specimens to release incorpo-
rated radioactivity by solubilization with a strong base.
The purpose of this project was to streamline the
solubilization process.
A solubilization method for quantitation of radioactivity
in whole tissues with tetraethylammonium hydroxide
(TEAH) was developed, and the process was automated
using a Zymark Zymate XP robotics system. Since
implementation in March 1996, a greater than 50%
reduction in tissue processing time compared to the
manual method has been achieved. Data quality has also
improved through uniform sample history, gravimetric
tracking and interfacing of the system output into our
laboratory data management processes. In addition,
safety was increased through lower chemical and radio-
chemical exposure and improved ergonomics when com-
pared to a manual method.
Automated assay and analysis of gels or liquid
detergent
Nick Barrett, InnovaSystems Inc. Pennsauken, 2VJ, USA
The AAAGOLD system is required to aspirate a sample
of liquid detergent and load the sample into cells for the
three measurements to be made: colour, viscosity and
pH. The measurement instruments are commanded to
initiate the measurements asynchronously, as each cell is
loaded. Data are then gathered by the system until a
stable reading is obtained. The fluid distribution com-
ponents must be washed, dried, and made ready for the
next sample. Concurrently, the robot and capper station
are replacing the current sample bottle and fetching the
next bottle from the sample racks. Each bottle is identi-
fied by a bar code.
The software implementation takes advantage of the
multi-threaded feature of the OS2 operation system.
High level functions such as control of each instrument,
or the distribution system, are executived on separate
threads to allow simultaneous processing of data collec-
tion, sample transport, and the GUI human interface.
An important feature of the system is the use of script files
to control the fluid handling part of the system. In this
way, the sample handling method may be modified by
the user using a simple, human readable, command set.
Script based fluid handling also allowed non-program-
mers to experiment with the sequence and other details of
the method during development and initial test. As part
of the diagnostics functions, test scripts exercise industrial
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switches, valves and pumps of the liquid distribution
system.
A separate software program was developed to collect the
data describing the sample and study, and handle the
post processing of the data. The program used Java to
implement a GUI for the input of formatted study
information, managing study files, and printing the bar
codes and generating sorted results files.
Zymark BenchMate Workstation automates
DNPH preparation ofPPM aldehydes in industrial
samples--II
Stephen L. Wellons, Cheryll R. Roberts, Robert J. Gentry and
Jack D. Cobb, Union Carbide Corporation, South Charleston,
fv, us4
The laboratory procedure for diluting, derivatizing and
extracting the 2,4-dinitrophenylhydrazine (DNPH) de-
rivatives of aldehydes in industrial samples takes about
15min of labour per sample. A sample preparation
Zymark BenchMate Workstation can do these steps in
an equivalent manner for 1-3 min of labour per sample.
In the poster presented last year, the DNPH derivatives
were extracted away from the acidic preparation matrix
with Solid Phase Extraction (SPE) cartridges before
liquid chromatographic (LC) injection. In this poster
the matrix is first neutralized and then injected directly,
saving time and cost. Using the BenchMate the five main
variables (pH, concentration of acid, organic solvent,
mixing time and mixing speed) were optimized fairly
quickly. The advantages and disadvantages of the two
approaches were compared.
Adapting a Zymark robot for extraction of metola-
chlor from soil
Theresa H. Lemme, Alan Olness, and Ward B. Voorhees,
USDA-Agricultural Research Service, North Central Soil Con-
servation Research Lab, Morris, MAr, USA
Current methods tbr extraction of metolachlor [2-chloro-
N-(2-ethyl-6-methylpheny )-N- (2-methoxy- 1-methy-
lethyl)-acetamide] from soil are tedious and time con-
suming. A procedure was developed to provide a quick
and reliable automated multi-step method of metolachlor
extraction from soil. A robotic solvent drying station
containing anhydrous sodium sulphate was configured
with a glass filter device. A custom made 27-mm OD by
20-mm 1D 1-mm-thick Teflon gasket was fitted between
the top and bottom portion of the filter to prevent solvent
leakage. A filter support was machined from a
100 50 18-mm aluminium bar and attached to the
liquid-solid station tower. A hole cut in the liquid-solid
station tower allowed repositioning of the pneumatic
toggle clamp. A cap closure assembly was prepared from
a 38 x 13-mm Teflon cylinder and attached to the
pneumatic toggle clamp. A 30-mm ID centrifuge tube
holder was fashioned from Teflon and positioned on the
liquid-solid station shuttle in the output position. The
robot was programmed to access the new station for
drying the hexane-metolachlor solution, use the pneu-
matic toggle clamp with the Teflon cap assembly to move
the sample into a large collection tube, and rinse the
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sodium sulphate with the appropriate solvent to ensure
removal of all the solvent-metolachlor solution. The
computer was programmed to divide each large centri-
fuge rack, use each of the four positions in the centrifuge
for four separate extractions, move the liquid-solid
station shuttle in to collect the dried hexane-metolachlor
solvent and use one position on a second master lab
station as a solvent dilution-delivery module.
Custom automation and the validation dilemma
Keith A. Gang, InnovaSystems, Inc., Pennsauken, NJ, USA
Various degrees of difficulty exist when validating custom
automated systems and workstations. This poster com-
pared the validation efforts of two equally complex
automated systems, both of which perform QC testing
in the pharmaceutical industry.
In the first case study, InnovaSystems was contracted to
validate a previously designed custom vision automation
system used for the real-time quality control inspection of
MDI patient actuators. The second case study involved
the validation of a bench-top workstation that auto-
matically performs a user defined sequence of spraying
and weighing of nasal spray pumps. This spray and
weigh workstation, InnovaSystems’ Automated Nasal
Spray Pump Delivered Volume Test Station, is delivered
with validation documentation.
InnovaSystems has been involved with the validation of
custom and ’off-the-shelf’ automated systems for the
pharmaceutical industry. InnovaSystems has validated
various automated systems and automated laboratory
equipment provided to its clients by third parties.
A comparison of the following issues with respect to the
influence that a validation provider has on them (i.e.
validation provided by the manufacturer as part of the
life cycle of the system versus validation provided by a
third party on an already designed system) was made for
the two case studies. The following issues were described
as they are perceived by the end user of the systems:
Validation cost.
System cost.
Quality.
Schedule.
Maintainability.
Usability.
Customizing your workstation’s controller
Simon Smith, SmithKline Beecham Pharmaceuticals, West Sus-
sex, UK
With the acceptance oflaboratory automation within the
industry, the move to improve its user interface has
emerged. Four years ago, we were all delighted when a
new workstation actually processed a single sample into a
final solution for analysis. Now, that automated process is
taken for granted. As a result, other ways to improve the
current laboratory automation are being sought. The
ultimate vision and inevitable goal of this new wave of
development is to produce a system where a tablet can be
put into the front end of an instrument and the finalAbstracts of papers presented at the 1997 ISLAR
result posted to a LIMS system for verification or printed
out for the operator to take away.
As a first step towards the ultimate analysis instrument,
the on-line automated checking of current equipment
performance has been developed within our laboratory.
Initially concentrating on system calibration and the
formatting of the gravimetric data, the progression
towards final results calculation can be seen. Remote
operation of the automation systems has also been
successfully achieved over a PC/PC link via modem.
The major hurdle being an interface with the chromato-
graphy data handling system.
There are two options for the ultimate analysis system,
the first being to use the system’s controller to perform
the calculations after transferring any necessary data
from the chromatography system. The second option is
to pass any gravimetric data to the chromatography data
handling system and have it perform the calculations.
The variations in data handling software on the market
today do not make this an easy task for an automation
vendor. For this reason, the first wave of the ultimate
analysis systems will be developed in house.
With the evolving use of the Internet, all robotic systems
could be programmed to add their errors into a globally
accessible database. This pool of information would
naturally be covered by appropriate security and would
allow the manufacturer to monitor each geographical
area enabling provision of the required service and
support infrastructure. Users could also, where per-
mitted, see which other laboratories were experiencing
similar problems.
After achieving these goals, what next? Totally remote
operation? Will operators on Mars be running the
laboratory robot systems down on Earth?
SEPBOXmautomated isolation of natural products
Kai U. Bindseil and Ralf God, AnalytiCon AG, Berlin, Germany
Natural products of plant, microbial and animal origin
are still high in demand as starting materials in screening
for new biologically active compounds. However, isola-
tion of pure substances from complex extracts is often
tedious, time-consuming and hence an expensive process.
To perform drug discovery in a more efficient way a fully
automated chromatographic device was developed. This
SEPBOX system is based on a skilful combination of
HPLC and solid phase extraction (SPE) technologically
realized as an HPLC/SPE/HPLC/SPE coupling. By this
technique, fractionation of an extract into 100-300 fairly
pure compounds is possible within less than 24 h. In this
way, SEPBOX guarantees an efficient provision of nat-
ural compounds for high-throughput screening. Ex-
amples for the automated fractionation of plant and
microbial extracts were discussed in detail.
Development of a method for accurately and
rapidly screening tight-binding enzyme inhibitors
Martin Wong, Duan Putnam and Grant Cart, Biochemistry,
Arris Pharmaceutical Corporation, S. San Francisco, CA, USA
The accurate determination of the affinity of tight-
binding enzyme inhibitors, with Ki values comparable to
the enzyme concentration used in the assay, has not been
routinely needed in the pharmaceutical industry until
recently. As our enzyme inhibition programmes pro-
gressed, the assay lab was faced with the problem of
measuring tight-binding inhibitors synthesized by our
chemistry divisions. Concurrent problems were the need
to minimize the turn-around time for results and to have
a method in place that anyone in the lab could use. We
have successfully developed and implemented a multistep
protocol for determining the apparent Ki of tight binding
inhibitors for several of the enzymes we routinely assay.
In this poster the authors presented the primary testing
method, where the inhibitor is quantitatively identified,
and the steps of the secondary assay, wherein Ki app. is
accurately determined.
Building a new integrated corporate HTS environ-
ment
Plamen Petrov, Ian Yates and Mark Divers, Astra HTS Centre,
Lund, Sweden
During the last year Astra has established and success-
fully turned into production a new corporate HTS
Centre. The unit is designed to serve projects from the
whole international Astra research organization, and also
to house the HTS compound library. Keys to the rapid
success of the facility are the tight integration between
biological screening and compound handling, the high
degree of automation and automated data management
and the freedom to build a system from the best or most
pragmatic options available on the market.
Our automation equipment currently includes two Zy-
mark robotic systems and a Tecan Genesis RSP. One of
the Zymark robots works as a dedicated liquid handling
system, while the other is a screening system capable of
running isotopic, fluorimetric and colorimetric assays. All
microtitre plates are barcoded and tracked in a database
(ActivityBase from IDBS, UK) during their whole life-
cycle along with the experimental data. Hits are ex-
tracted from the source plates using the Tecan
processor for further testing.
A further robotic system (from Thurnall, UK) for
automated screening is currently being installed. It will
be closely followed by an automated liquid store system
(Thurnall) which will house the compound source and
replicates and will eliminate all manual work in plate
preparation and sampling handling.
The system is currently operational at genuine high
throughputs with 96-well technology, but is well-placed
to exploit other formats, new technologies and higher
capacities. This is partly due to the choice of instrumen-
tation and design, but mostly because of the well-
integrated nature of the Centre, combining both the
compound library and screening activities, linked by
common data and automation strategies.
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The Microbial product library for high through-
put screening at Biosearch Italia
Daniel Losi, Angelo Borghi, Linda Cavaletti, Frederica Sponga,
Ameriga Lazzarini, Marco Monti and Flavia Marinelli,
Biosearch Italia SpA, 34, Gerenzano, Italy
Microbial diversity is an important source of new
pharmacologically active molecules, novel molecular
templates for target-oriented combinatorial chemistry,
as well as new biocatalysts. The exploitation of microbial
diversity requires the access to geographically diverse
sample sources and to different ecological niches, the
employment of enrichment and/or selection methods for
the isolation, and the development of a high-quality
process for the preparation/use of samples in high-
throughput screening (HTS).
The Biosearch Italia microbial collection contains ap-
proximately 22 000 microorganisms represented by 27%
streptomycetes, 24.5% fungi and 48.5% actinomycetras-
pora, Actinoplanes. From 1960 to the present, thousands
of strains had been isolated per year, but only those
showing peculiar taxonomical or metabolic traits have
been maintained in the collection. Today, the microbial
diversity is continuously enriched by combining propri-
ety isolation methods and selective media and by isolat-
ing from different sources such as soils, leaf litter, marine
and lake sediments and plants.
A microbial product library is currently being generated
by fermenting strains in multiple media to enhance the
expression of microbial diversity. Samples are prepared
by resin absorption/elution of the fermented broths,
dispensed in 96-wells microplate format and ready to
be used in HTS. The process of sample preparation is
completely automatized by using a robotic station based
on Zymark technologies and customized by FKW (the
Zymark Italian subsidiary). This robotic station is able to
work up to 320 fermentation broth per day employing
two different sample treatments (one in development
phase), and thus to generate 640 samples per day.
The data management of the microbial collection, the
microbial product library, the process for the sample
generation, and the results of the tests/projects of their
screening requires the development of a complex infor-
mation system. A customized version of Perkin Elmer
SQL*LIMS ORACLE-based data management has
been developed for the integration of the standard
package with new forms. All the information related to
each strain in the collection has been linked with the data
related to each sample (for example the producing
microorganism, the fermentation medium and the
sample preparation method). The results generated on
the microbial sample in the HTS assays are also main-
tained and handled by the same data management
system which guarantees the analysis and the retrieval
of the data.
High throughput liquid handling at Glaxo Well-
come
James Ballinger and Makda Mebrahtu, Glaxo Wellcome Inc.,
Research Triangle Park, NC, USA
Liquid handling is a recently added function of the
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Compound Registration department. Until last year, the
only method of filling compound requests was weighing
out solid samples manually, which proved to be time-
consuming and wasteful of limited supplies of research
compounds. Once a small quantity of solid sample is
dissolved in a diluent, then this liquid supply is sufficient
for numerous requests. Handling compounds in solution
is essential for the high throughput screening programme
introduced at Glaxo Wellcome’s US site in mid-1996.
Samples dissolved in DMSO are packed in 96-well plates
and the data associated with these plates, such as volume,
concentration, and plate maps are transferred into a
liquid inventory system. This inventory system generates
barcodes containing updated information pertaining to
the aliquoting, diluting, or pooling method applied to the
original plates. The tasks created in the database are then
carried out physically in barcoded plates by means of a
Zymark RapidPlate and Tecan Genesis. Aliquots are
then distributed to designated screen sites. After testing,
the compounds considered to be of interest are selected
and resubmitted for further testing.
Over the last year we have provided over 365 000 liquid
samples to the screening sites of R&D. In the future, we
plan to address and improve aspects of liquid handling
such as cold storage, stability, plate labelling and solubil-
ity, as well as to explore new automation techniques.
Fully automated compound distribution to mul-
tiple biochemical targets
Joan Frezza, Julie Tomlinson, and Brent Butler, Glaxo Well-
come Inc., Research Triangle Park, NC, USA and Matthew
Klemp, Zymark Corporation, Hopkinton, MA, USA
Drug discovery in the 1990s has adopted high through-
put screening to increase productivity by quickly evalu-
ating the vast numbers of compounds generated through
compound libraries and other synthesis technologies.
High throughput screening necessitates the replication
and dilution of hundreds of thousands of compounds,
which are today formatted and stored in 96-well plates.
These compound plates are subsequently tested for
biochemical activity against multiple targets.
In the early stages of screening, compounds were diluted
and dispensed using RapidPlate and Tecan workstations
operated by people; plates were labelled and sealed
manually. Just dispensing compound required the work
of five full-time people 10 days/month. All of this work is
now fully automated.
To facilitate this process, GlaxoWellcome’s Department
of Molecular Biochemistry worked with Zymark Cor-
poration to fully automate its compound-handling pro-
cess. Together they engineered a system which integrates
a Tecan Genesis 150, two Zymark Rapid Plates, three
storage carousels and six random racks with a 3-m under-
table track and a Zymate XP robot. The system’s liquid
handling performance is routinely verified and its com-
pound handling processes are frequently changed to meet
the changing needs of GW’s biochemistry processes.
At the time of this presentation, this compound handling
robot had been operational for six months and hadAbstracts of papers presented at. the 1997 ISLAR
prepared tens of thousands of compound plates for GW
biochemical targets.
Automated sample preparation for drug discovery
with modified Zymark RapidTrace modules
I. Schmid, I. Sattler, S. Grabley and R. Thiereck, Hans-Knoell-
Institute, Jena, Germany
Secondary metabolites from plants, animals and micro-
organisms show a structural diversity that chemically
synthesized compounds can hardly reach. For this reason
natural products are interesting sources for automated
screening programs in drug discovery. Unfortunately,
extracts from natural sources are usually complex mix-
tures of compounds. As the quality of the provided
samples play a pivotal role in the success of high
throughput screening programmes this poses serious
problems. A method of sample preparation which re-
duces complexity and simplifies the identification of an
active compound from a mixture would avoid tedious
and time consuming steps in the drug discovery process.
This presentation described a new automation approach
of sample preparation with eight modified Zymark
RapidTrace modules. The workstation was designed
and set up in co-operation with Zymark GmbH, Ger-
many. A fast and easy-to-handle sample preparation
method was developed, which is based on multistep solid
phase extraction (SPE). A combination of chromato-
graphic procedures and final concentration step are used
to efficiently separate complex mixtures of compounds
from natural sources. The procedure allows the genera-
tion of fractions of highly reduced complexity close to
almost pure compounds. Depending on the complexity of
the starting material and the purpose of the fractionated
sample, the method allows any number of fractions,
typically between and 70, to be generated.
Using these fractions in automated biological assays
makes test results much more reliable and reproducible.
Furthermore, the quality of the provided samples allows
them to be analysed without further treatment with
methods like HPLC, TLC, NMR and MS. That enables
rapid identification and structure elucidation of active
compounds, as well as the recognition of known or
already isolated metabolites.
The new screening centre at the Hans-Knoell-
Institute for national products research
R. Thieriecke, If. Undisz and S. Grabley, Hans-Knoell-Institute,
Jena, Germany
The Hans-Knoll-Institute of Natural Products is an
independent non-profit research institute in close part-
nership with the Friedrich-Schiller-University of Jena.
Founded in 1992, the institute’s purpose is the advance-
ment of basic institute is organized in the divisions of
Microbiology, Chemistry, Bioprocess Development, and
Drug Discovery.
As a recent addition to the Hans-Knoll-Institute a
screening centre has been established. The screening
centre meets all the requirements for running efficient
and successful drug discovery programmes in collabora-
tion with industrial partners focusing on medical and
agrochemical applications. The focus of our current
research activities and ongoing projects are the realiza-
tion of different screening programmes, the automation
of new screening assays, the development of new sample
generation procedures, and the bioprocess development.
In addition to these applied aspects of drug discovery
research the centre also carries out basic research towards
the identification of new molecular targets.
Homogeneous assay methods: the future of high
throughput screening miniaturization
Alfred j. Kolb, Packard BioScience Company, Meriden, CT,
USA
There are two major reasons why it is generally believed
that homogeneous or non-separation assays will be
required to meet future screening goals. These are time
and miniaturization.
Even simple and relatively rapid steps like plate washing
take on an entirely different time scale now that through-
puts of 500 plates/day/target (50000 samples) are poss-
ible. Semi-automated workstations are too labour
intensive and tedious to be used with these throughputs.
It is clear that a greater level of fully robotic automation
will be required. Even though washing and filtration
steps have been automated, homogeneous, mix and
measure methods are much faster and far more practical
for the required throughputs. While it doesn’t seem like
much, saving min per plate with a 500 plate/day
throughput adds up to a saving of 8h a day. Homo-
geneous assays can save far more than this when one
considers the time it takes to coat and wash plates or to
separate by filtration or centrifugation. This far more
efficient use of robotic workspace has an additional
benefit of reducing the cost of equipment and facilities
space.
Screening scientists cannot meet their throughput goals
without miniaturization. While the 96-well plate is still
the standard, the 384-well plate and the necessary
equipment to process them are available. There are
already significant advances being made in the develop-
ment of 864-, 1536- and 3456-well plates. At some level of
miniaturization, the methods commonly used in today’s
lab will no longer be practical. For example, the use of
filtration as a separation step has been the cornerstone of
receptor binding assays. However, there are currently no
384-well harvesters available so this method will prob-
ably be restricted to the 96-well format. Coating and
washing for in-plate binding assays is now being done in
384-well plates, but it is not clear if this will be practical
when the use of 864-well plates becomes routine. Homo-
geneous assays eliminate the need for any of these
additional steps and the variability they add to the
results.
Fortunately, there are now a variety of homogeneous
(completely in solution) and non-separation (solid sup-
port attachments) assay technologies available that cover
a wide range of targets such as biomolecular interactions
(receptors, immunoassays, protein binding), enzymes
and cellular assays. They are also available with radio-
isotopic, luminescent and fluorescent signals. The choice
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of assay technology has a significant impact on the level
of miniaturization. As assay volumes are reduced from
100-200gl (96-well)to 25-50gl (384-we11), 10-15tal
(864-we11) and lower, the signal being measured becomes
critical. Because of half-life, specific activity and safety
issues, there is a limit to how much signal can be obtained
from a radioisotopic assay. Lower amounts of radio-
activity can be quantitated, but the increase in counting
time is contrary to the goal of high throughput screening.
This will set a limit on miniaturization. In contrast,
luminescent and fluorescent assays can achieve much
higher signals for a greater degree of miniaturization.
Examples were given of the miniaturization of isotopic,
luminescent and fluorescent assays for biochemical and
cell-based assays.
Automated distribution of solid support
Peter Kieselbach and Gregory L. Kirk, Pharmacopeia, Inc.,
Princeton, 2vj, USA
Commercial-scale combinatorial synthesis on solid sup-
port requires the distribution of large quantities of solid
support resin, or beads, with stringent demands upon
accuracy, cleanliness and throughput. Hundreds of thou-
sands to millions of microscopic polymeric beads must be
deposited into containers or microplate wells in a method
which allows control over the number of beads deposited
and which causes no damage or contamination.
Pharmacopeia and SCITEC (Wilmington, DE) have
developed an automated system for distribution of solid
support from bulk containers to 96-well microplates
employing volumetric transfer of an isobuoyant suspen-
sion. Consumables are stored in automated carousels and
transported through the system by a CRS robot. Volu-
metric delivery is accomplished by a Zymark RapidPlate
pipeting workstation and the plates, containing the solid
support beads, are washed by a Pharmacopeia-developed
apparatus and dried in a vacuum drying oven.
The process challenges, architecture and performance of
this automated system were presented and other methods
of delivery discussed, including an automated bead-
counting device for accurate delivery of an arbitrary
number of beads, down to one bead per well.
Bar codes and other long term identification
methods for microtiter plates in high throughput
screening
Kevin K. Olsen, Wyeth-Ayerst Research, Pearl River, NY, USA
Management of the large numbers of microplates used in
a high throughput screening environment requires reli-
able marking methods. Typical conditions to which
plates are subjected include solvents, rough handling
and repeated freeze/thaw cycles from extreme cold room
temperature and back again.
The problem is complicated by the nature of polypropy-
lene which is commonly used for the initial compound
dispensation. Polypropylene and its co-polymers are
resistant to most solvents used in compound dissolution
and distribution. Unfortunately, they are also resistant to
inks and some label adhesives.
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The labels can consist of one-dimensional bar codes for
simple identification. These are highly reliable, easy to
print and simple to read. More elaborate two-dimen-
sional bar codes can both identify the plate and encode
information about it. They are also highly reliable.
Labels that are scratched, torn, or applied to irregular
surfaces are still readable. The principle disadvantage is
that they can only be read with specialized scanners.
One efficient marking method is polyolefin labels with
acrylic based cold temperature adhesives. Another hi.ghly
effective method is laser engraving. Wyeth Ayerst’s
Research Compound Bank uses this system for plates
that are intended for long term storage. Other advanced
identification methods include ’smart’ tags that contain a
memory chip that is activated by direct contact with a
reader or by radio.
Whatever system is utilized, the ultimate goal must be
reliability. Paying attention to details such as adhesives,
label stock and bar code selection will result in years of
trouble-free identification.
A new fully automated mass spectrometer for
confirmational analyses in drug development
Karl-Heinz Maurer, Harald Gerken and Martin Maurer, AMD
Intectra GmbH, Germany
An AMD M-40 DF magnetic sector mass spectrometer of
benchtop design is used in combination with a Zymate
robot system to provide high throughput MS analyses in
Direct Chemical Ionization (DCI)-mode. The system has
been in operation for several months in the analytical
laboratory of the drug research group of a large German
pharmaceutical company. The major analytical target
for this system is the automatic confirmation of molecular
weights in combinatorial synthesis under high sample
throughput confirmations with very high statistical prob-
abilities and proves to be a very efficient and comple-
mentary method to ESI techniques. For a number of
substance classes the DCI technique is the method of
choice. The system functions were described, and the
results presented.
Automated Grignard addition to Weinreb amides:
use of air-sensitive reagents on the Nautilus 2400
Tracy Deegan, John A. Porco, Jr and Glynn S. Searl, Argonaut
Technologies Inc., San Carlos, CA, USA
The Nautilus 2400 synthesizer was used to automate the
addition of Grignard reagents to Weinreb amide deriva-
tives on solid support. The utilization of air and moisture-
sensitive Grignard reagents demonstrated the utility of
the Nautilus’ inert fluid delivery system.
Evaluation of matrix pooling
identification: a case study
process in lead
Dennis J. Murphy, Peter J. Bouchard, Steve J. Link, Angela H.
Gillespie, Wayne G. Carey and Thomas D. Y. Chung, DuPont
Merck Pharmaceutical Company, Wilmington, DE, USA
As chemical files increase in size there are pressures to
increase the throughput of compounds tested whileAbstracts of papers presented at the 1997 ISLAR
reducing cost of assays. One solution is to test pools of
compounds. However, the increase in efficiencies are
offset by the time and costs of retests and deconvolution,
as well as the concern about the additive effects and
masking effects of compounds. Matrix pooling is a
method that functionally results in each compound being
tested twice, each time with a different cohort of
compounds, and theoretically eliminates the need to
reassay each individual member of an active pool. We
have screened a relatively large chemical files against a
clinically relevant protease target both in pools and in
singles, using a robust fully robotized assay. The data
provide an additional case study of the necessary decon-
volution processes and provide a comparison and analysis
of the leads identified or missed by screening compounds
in pools versus individually.
Use of an automation compatible 24-well insert
system for various cell based assays
Amy Goldberger, Paul LaRocca, and Darwin Asa, Becton-
Dickinson Labware, Bedford, MA, USA
In recent years, the use of cell based assays for drug
screening applications has increased tremendously. How-
ever, some cell based assays are difficult to use in a highly
automated screening laboratory setting due to special
handling conditions required for cells, or general format
incompatibility of the assay platform with automation
equipment. This is particularly true of cell based assays
requiring the use of microporous membranes. Current
microporous membrane systems for cell based assays
utilize individual inserts which are not amenable to
automation equipment. To overcome these barriers to
using cell based assays in an automated screening setting,
we have developed an automation compatible 24-well
insert system for use in cell-based assays and tested the
system in several cell-based applications.
Using a unique 24-well insert format, we have produced
insert systems incorporating either a 1.3 or 8 gM PET
membrane for different cell-based applications. The tam
PET system has been tested for its ability to support the
differentiation of CACO-2 cells used for drug perme-
ability studies. The 3 gM system has been tested for its
ability to support neutrophil migration in response to
chemototactic gradient. While the 8 gM system has been
tested for its ability to support an assay for tumour cell
invasion through an extracellular matrix protein layer.
The data presented demonstrated the utility and per-
formance of this system in several commonly used cell
based assays.
Automated parallel synthesis of olefins
Joseph M. Salvino, Rhone Poulenc Rorer, Collegeville, PA, USA
The Wittig and Horner-Ennomons condensation reac-
tions are attractive and versatile methods to generate
carbon-carbon bonds, producing olefins as products. The
Wittig reaction has been utilized extensively on solid
support, as well as the Horner-Emmons reaction. A
process to produce ,[3-unsaturated resin bond benzyl
esters has been semi-automated, greatly facilitating the
parallel solid phase synthesis of olefins for either biologi-
cal testing or further synthetic elaboration. The automa-
tion protocol was described, including reagent weighing,
robotics synthesis, evaporation, sample weighing and
dissolution in preparation for high throughput screening.
A versatile robotic system for the automated
organic synthesis of compound libraries in the
drug discovery process
Will Kuijpers and Ton Jenneboer, JVV Organon, OSS, The
Netherlands; Eugy Van Gool, Labotec JVV/SA, Teralfene,
Belgium
Within pharmaceutical companies there is a growing
tendency to integrate automated synthesis systems into
drug discovery research. With the aid of organic synthe-
sizers, techniques such as solid-phase organic chemistry
and combinatorial chemistry can be fully implemented in
the drug discovery process. Several synthesizers have
already been commercialized and are often integrated
as workstations in semi-automated synthesis streets.
This paper described the development of a versatile
robotic system which takes care of the entire synthetic
process, including workup of the products (evaporation,
extraction). The system is capable of performing both
reactions on solid-phase and in solution.
The heart of the system is a new Zymark BenchMate-
based synthesis block called LaMOSS (Labotec Modular
Organic Synthesis System). This synthesis block contains
48 reactors with a reaction volume of 5 ml, organized in
six units of eight reactors. Solvents, reagents and building
blocks are added by a robotic arm, located in the centre
of the units. LaMOSS further contains storage racks for
tubes, building blocks and reagents, as well as a vessel to
collect the resin in split-pool syntheses. Reactions are run
under inert atmosphere (nitrogen). The reactors can be
cooled or heated by air from a thermostration unit.
Reflux conditions can be applied as well since the top
side of the reactors can be cooled to 10C. After comple-
tion of the synthesis and in case of a solid-phase synthesis
after cleavage from the resin, the products are collected in
glass test tubes. Subsequently, the tubes are placed in a
shuttle and transferred to a Zymark XP robot which
takes care of the workup of the samples. The latter
process involves evaporation of solvents, and a liquid/
liquid extraction to purify the products.
The robotic system has been operational since January
1997. A full description of the various elements was given,
with the emphasis on the LaMOSS synthesis block.
Results of a number of syntheses performed on the system
were evaluated.
Automated system for solid phase synthesis of
combinatorial libraries
Rajesh K. Maheshwari, Alex Berenshteyn, Bernard 2Veustadt,
and Elizabeth M. Smith, Schering Plough Research Institute,
Kenilworth, NJ, USA
A robotic synthesizer has been developed to accelerate
the generation of combinatorial libraries of molecules
using solid-phase chemistry. This instrument has been
in operation since January 1997. Libraries of single
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compounds and mixtures have been synthesized using
this instrument, and HPLC and mass spectroscopic
characterization of the products have shown very good
purity.
The instrument completely automates the liquid hand-
ling operations of this process, and it is used for con-
tinuous batch-wise operation to provide regular output of
samples for testing. It reliably handles the extensive data
involved with synthesis of thousands of component mol-
ecules.
Several engineering challenges were overcome in devel-
oping a modular reaction block, which accommodates
reaction vessels of 15 to 1201 capacity. It can also
conduct solid phase chemistry with resin-loaded micro-
reactors. The top module of the reaction block is light
enough to be removed from the system by the chemist
with the reaction vessels maintained under inert atmo-
sphere. Thus, it can be placed on external shakers,
heaters, or chillers.
In addition to the modular reaction block, modular trays
have been developed to hold the building blocks and
reagents. The instrument is computer controlled, and the
operator can manually intervene at any time in the
reaction cycle and then restart the reaction in automatic
mode.
A chemist-fidendly programming language, SPOSL, has
been developed through which the chemist can program
the synthesis, making this instrument very versatile and
flexible. Dispensing of building blocks and reagents can
be specified by volume or as molar equivalents relative to
the scale of the synthesis. Any existing multi-step method
is readily modified to create a new method.
A special graphical synthesis planner has been developed
in the software which allows the chemist to plan the
synthesis graphically on a reaction vessel basis. For the
purpose of compound registration, provision has been
made for a link with external registration and enumera-
tion software.
Automated organic synthesis and process optimi-
zation
Peter Hilberink, Frans Kaspersen and Eugy van Gool, 2V.V.
Organon, The 2Vetherlands and Labotec 2VV/SA, Teralfene,
Belgium
In 1994, a Zymark XP synthesis robot was installed at
Organon for reaction optimization. This robot is able to
start, control and finish organic reaction without super-
vision. Experimental design is used to efficiently run the
experiments and to analyse the data generated by the
robot.
During the last three years, some very useful results have
been achieved, but we also identified some shortcomings
of the system. The major one is that the system is not able
to analyse the samples immediately. Because samples
have to be analysed offtine by GC or HPLC, they are
stored for a period of time and are usually several hours
old (up to 24h) before analysis. During this time, the
samples are undergoing degradation which influences the
outcome of the experiments. In some cases, the results
5O
were highly questionable and the experiments had to be
cancelled.
Because we were able to acquire a second Zymate II
robot, we saw a chance to eliminate this shortcoming.
The Zymate II receives the samples from the synthesis
robot and performs sample preparation and HPLC
injection. The design and some experiments were dis-
cussed.
Automated dissolution using Zymate Assisted
MultiDose (ZAM) and integrated HPLC system
Scott Jennings, Bristol-Myers Squibb, New Brunswick,
USA
An automated dissolution system which integrates a
MultiDose (R) Workstation, Zymate XP (R) robot and
Hewlett Packard HPLC has been developed. This unique
system allows us unattended dissolution analysis of the
solid oral dosage form which needs chromatographic
finish. ZAM allows us to transfer capsules and tablets
to the MultiDose(R), collect samples into HPLC vials and
finally transfer the sample vials to the HPLC autosam-
pler and back to the storage rack after the analysis. The
unique features of this integrated system are that it
performs HPLC analysis of the dissolution samples as
they are collected and requires no manual transfer of the
samples to the HPLC autosampler. It will also automate
the removal of capsule sinkers at the end of a dissolution
run thereby allowing us to test encapsulated products.
This system will increase sample throughput by about
50% compared to a standard MultiDose(R). A sizable
productivity gain compared to the existing robot serial
dissolution system is also expected.
Excel (R) is the control program that monitors the dissolu-
tion activity on the MultiDose and the progress of the
HPLC analysis of the HP 1050 system. Two-way com-
munication between Excel(R), HP Chemstation, Multi-
Doseq and System V (R) is achieved using Dynamic Date
Exchange (DDE), serial RS232 communication and
Zymark’s Visual Basic-VBX (R). In this presentation, the
innovative hardware, software, and communication
pathways were discussed. The presentation summarized
the challenges encountered during the ruggedness testing
and validation of such a complex system.
Validation techniques for an automated dissolu-
tion system
Daniel C. Hunneyman, Susan G. Kelley, Michael D. Stroz,
Wyeth-Ayerst, Analytical Research & Development, Pearl River,
v, usi
The Zymark MultiDose system has proven itself to be a
valued analytical tool for dissolution laboratories. How-
ever, the MultiDose system validation and the transfer of
validated manual methods to the MultiDose system have
been a time-consuming obstacle for most laboratories.
An approach to simplifying MultiDose system validation
and the cross-over validation of manual methods will be
discussed. The presentation illustrated validation on the
basis ofproving equivalency to a manually operated USP
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three days to perform, and the proposed transfer of a
validated manual method requires two days to perform.
The effect of various operational parameters on
the delivery of product through the valve of
metered dose inhalers
David Radspinner, Rhone-Poulenc Rorer, Collegeville, PA, USA
An automated system has been designed, constructed,
qualified, validated and implemented in our laboratories
for the determination of dose-delivered-through-the-
valve of various metered dose inhalers. This system is
capable of wasting, collecting, weighing, and assaying by
UV and HPLC. An experimental design was implemen-
ted to study the effect of a variety of parameters on the
delivery of product through the valve. The levels of each
parameter in the computer-aided experimental design
were automatically input into the aerosol robotics system.
The wasting and collection stations are capable of
variable control of the shake speed and time, actuation
duration, post-actuation delay, post-shake delay, and
total number of actuations. An overview of the system
design, the experimental design, and the results was
given.
Automating the analytical laboratory
chemical analysis automation program
via the
Robert Hollen, Los Alamos National Laboratory, Los Alamos,
NM, USA
To address the need for standardization within the
analytical chemistry laboratories of our nation, the
CAA (chemical analysis automation) program within
the US Department of Energy, Office of Science and
Technology within the Robotic Technology Develop-
ment Program is developing laboratory sample analysis
systems that will automate the environmental chemical
laboratory. The current laboratory automation para-
digm consists of islands and automation that do not
integrate into a systems architecture. Thus, today the
chemist must perform most aspects of environmental
analysis manually using instrumentation that generally
cannot communicate with other devices in the labora-
tory.
CAA is working towards a standardized and modular
approach to laboratory automation based upon the
Standard Analysis Method (SAM) architecture. Each
SAM system automates a complete chemical method.
The building block of SAM is known as the Standard
Laboratory ModuleTM (SLMTM). The SLM, being
either hardware or software, automates a sub-protocol
of an analysis method and can operate stand-alone or as a
unit within a SAM. The CAA concept allows the chemist
to assemble an automated analysis system, from sample
preparation through data interpretation, using standard-
ized SLMs easily and without the worry of hardware or
software incompatibility or the necessity of generating
complicated control programs. A Task Sequence Con-
troller (TSC) software program schedules and monitors
the individual tasks to be performed by each SLM
configured within a SAM. The chemist interfaces with
the operation of the TSC through the Human Computer
Interface, a logical, icon-driven graphical user interface.
The CAA paradigm has successfully been applied in
automating EPA SW-846 Methods 3541/3620/8081 for
the analysis of PCBs in soil matrix utilizing commercially
available equipment in tandem with SLMs constructed
by CAA. The presentation included a short video show-
ing the operation of the system.
TM Standard Laboratory Module and SLM are trade-’
marks of SciBus Analytical Inc.
A standard analysis method for the automated
analysis of polychlorinated biphenyls (PCBs) in
soils using the chemical analysis automated para-
digm: validation and performance
Charles Rzeszutko, C. Robert Johnson, and Matthew Monagle,
Los Alamos National Laboratory, Los Alamos, NM, USA, and
Leon N. Klatt, Oak Ridge National Lab, Oak Ridge, TAr, USA
The CAA programme, sponsored by the Robotics Tech-
nology Development Program within the Office of
Science and Technology, US Department of Energy is
developing a standardized modular automation strategy
for chemical analysis. In this automation concept, analy-
tical chemistry is performed with modular building
blocks that correspond to individual elements of the steps
in the analytical process. With a standardized set of
behaviours and interactions of the blocks, these blocks
can be assembled in a plug-and-play manner, into a
complete analysis system. These building blocks, which
are referred to as Standard Laboratory Modules
TM
(SLM’M), interface to a host control system that orches-
trates the entire analytical process, from sample prepara-
tion through data interpretation. The integrated system
is called a Standard Analysis Method (SAM).
A SAM for the automated determination ofPCBs in soils,
assembled in a mobile laboratory, has undergone ex-
tensive testing and validation. The SAM consists of the
following SLMs: a four-channel Soxhlet extraction, a
high-volume concentrator, an extract clean-up, a gas
chromatograph, a data-interpretation module, a robot,
and a human-computer-interface. The SAM is config-
ured to meet all the requirements specified in US EPA
SW-846 Methods 3541/3620/8082 for the analysis of
PCBs in soils. Once the input queue is filled, samples
are automatically completed in intervals of 30 min. The
PCB SAM was described along with the validation
strategy. Validation and performance data from the
testing protocols was discussed.
TM Standard Laboratory Module and SLM are trade-
marks of SciBus Analytical Inc.
A total suspended solids automation system with
a graphic user interface using spreadsheet data
handling
j. j. Zieman, P. L. Morabito, R. Tamilarasan, Dow Chemical
Company, Midland, MI, USA; P. D. Hazelwood, Dow Chemi-
cal Company, Sarnia, Ontario, Canada and S. Sayers, Dow
Chemical Company, Texas Environmental Analytical Laboratory,
Freeport, TX, USA
The Automation Team of the Dow Chemical Company
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has developed a Total Suspended Solids (TSS) automa-
tion system for environmental water sample analyses.
The system uses Gooch crucibles with glass fibre filters
to collect the solids from water samples. The crucibles are
placed into a desiccation system with removable stainless
steel racks. Sample delivery is performed using a peri-
staltic pump into a custom filtration station. Later, the
crucible racks are manually placed into the drying or
ashing oven. Dried TSS samples may be further pro-
cessed by ashing to determine the Volatile Suspended
Solids (VSS) content. This system can process a total of
60 samples per run without dilution or 30 samples with
dilution before filtration.
A Microsoft(R) Visual Basic (R) graphical user interface was
developed to incorporate point and click control of the
system, including automated pump calibration. The
graphical user interface incorporates all data entry and
output into Microsoft Excelw spreadsheets. This auto-
mated data handling was essential and has allowed
interrupted runs during off line drying or ashing of other
batch samples.
Microvolume screening of combinatorial libraries
in high-density microtiter plates
Jonathan j. Burbaum, Pharmacopeia, Inc., Cranbury, jvj, USA
High-throughput screening (HTS) is a well-established
method for the discovery ofnew pharmaceuticals. HTS is
now becoming a focus for technological development
because of significant advances in both combinatorial
chemistry and genomics, which are increasing both the
number of compounds and the number of targets.
Pharmacopeia is pursuing a HTS-New Technologies
(HTS-NT) system, which revolves around microlitre
volume assays in 1536-well microtiter plates. This system
has clear benefits not only to Pharmacopeia’s drug
discovery efforts, but also in many other arenas. Lower
volume bioassays are widely advantageous, conserving
both target reagents and compound collections. Reduc-
tions in volume also allow samples to be arrayed at higher
densities to increase sample throughput.
This system presents a number of technological chal-
lenges to both biologist and engineers. A wide range of
bioassays, including enzymatic, receptor binding, and
cell-based assays need to be addressed in a microvolume
format. Further, to carry out these assays in an efficient
manner, improvements in liquid handling and detection,
as well as the design and molding of new containers, will
need to be implemented. The authors’ approach toward
meeting these challenges was discussed.
Integration of the GENESIS with
ACTIVITYBASE for SAR screening
RoMa and
G. R. Baker, C. R. Molloy, M. A. Snowden and P. Osbond,
GlaxoWellcome R&D, Stevenage, UK
The SAR Group from the Enzyme Pharmacology De-
partment provides enzymological expertise to the medic-
inal chemistry programmes that run within the UK. The
support of primary and selectivity assays across a number
of therapeutic areas requires us to present, test and track
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compounds through over 40 assay protocols concurrently
with minimal human resource. We have integrated AB
(ACTIVITYBASE--ID Business Solutions) and two
Tecan GENESIS with RoMa systems to achieve robotic
flexibility with the workflow management and com-
pound tracking that is required.
AB is a WINDOWS-based application that can be used
to manage the many aspects of activity testing (i.e.
compound tracking, data analysis and data storage).
We have customized this application by developing
modules that provide automated QA, internet publishing
of SAR data, sample archive management and an inter-
face to the Tecan GENESIS with RoMa called ROBOT-
SERVER. This VB interface polls the AB database for
’Test Request’ which are compound lists that have a
series of robotic ’Actions’ assigned to them. As each batch
of work is received, ROBOTSERVER constructs all of
the relevant TLS (Tecan LOGIC Software--Kubus)
INI and JobList files and initiates the RCS (RoMa
Control Software--LaboSoft) scripts that control each
GENESIS, from data retrieved from the AB ORACLE
tables. This provides the group’s scientist with an easy-to-
use interface to the complex suite of robotic software
ensuring that compound solvation and sample presenta-
tion is always consistent with the AB ’Protocols’ selected
to analyse the assay data, irrespective of the sample
format. Current features include the ability to queue
and prioritize the batches of work from multiple remote
NT workstations and to manage a 100-plate custom hotel
resource on each of the GENESIS systems. The develop-
ment of the system was discussed, together with future
plans, including the integration of a new scheduling
program into this system.
Use of the Zymark RapidPlate-96 to perform
pipet-in-a-tip assays for high throughput screen-
ing
Crafford Harris, Ruth Brosius, and Mary Jo Wildey, The R. W.
Johnson PRI, Raritan, 2VJ, USA and Andy Zaayenga, Zymark
Corporation, Hopkinton, MA, USA
In Drug Discovery at the R. W. Johnson Pharmaceutical
Research Institue, high throughput screening is a dy-
namic programme whose objective is to maximize the
effectiveness and efficiency of the drug discovery effort,
resulting in the identification of new and novel pharma-
cophores. To that end, new concepts and techniques in
reagent handling are always being investigated. One of
the tools currently used in our programme is the 96-
channel pipettor which is integrated into a custom Zy-
mark robotic system. Two time consuming steps in an
HTS screen are moving tip racks to and from the work
surface and accessing assay plates multiple times to add
multiple reagents. One obvious way to increase screening
efficiency would be to limit the number of these types of
robotic arm movements by utilizing the ’pipet-in-a-tip’
concept. In this technique, all assay reagents are aspi-
rated into a single pipet tip, with each reagent separated
by an air gap to reduce preincubation problems. When
one uses a 96-channel pipettor to accomplish this task,
the throughput is enhanced even more. We have eval-
uated the Zymark RapidPlate-96 on our custom roboticAbstracts of papers presented at the 1997 ISLAR
system for this task. In this presentation the authors
outlined this pipetting strategy and provided data on
how this technique has worked.
Development of an automated, high throughput
reporter gene assay
Richard K. Harrison, Research Fellow, New Lead Generation
Department, Rhone-Poulenc Rorer, Collegeville, PA, USA
In the last few years the pharmaceutical industry has
witnessed an increase in the number of high-throughput
cell-based assays. Due primarily to advances in molecular
biology, simple, robust reporter gene assays capable of
monitoring and reporting on transcription events is now
commonplace. However, as with most high throughput
screens, many problems are met when taking an assay
from the manual, one-plate (’bench’) scale to an auto-
mated, multi-plate scale. This talk focused on the im-
plementation and validation of several automated high
throughput reporter gene assays, highlighting the advan-
tages and disadvantages of each, and offered solutions to
several of the common problems associated with imple-
mentation of these assays.
Integration and organization of an HTS Group
within drug discovery
Michael Snider, Berlex Bioscience, Richmond, CA, USA
Empirical screening has become a routine technology in
early drug discovery research in the pharmaceutical and
biotechnology industry. While the specifics ofhow screen-
ing is accomplished between organizations (robotics
versus workstations; pooling versus single compounds),
there are still many similarities. However, there are two
factors which are often underestimated in terms of
importance for success: the organization of the screening
group within Discovery Research, and the nature of the
specific biological targets which are chosen for screening
efforts. Additionally, the human element of the auto-
mated screening operation was discussed, as well as the
impact of genomics on Discovery Research dynamics.
The integration of parallel combinatorial unit
chemical synthesis and multiplexed, high
throughput bioassays to accelerate drug discovery
Stewart D. Chipman, Adrian Sheldon, John Petracca, David S.
Casebier and Joseph C. Hogan, ArO.,ule, Inc., Medford, MA,
USA
Scientists engaged in drug discovery have benefited
greatly by the application of laboratory/industrial-scale
automation to both biological testing to enable high-
throughput bioassays, as well as chemistry to enable
parallel combinatorial chemical synthesis. The authors
described an approach to the integration of parallel
combinatorial unit synthesis and high-throughput bioas-
says that maximally accelerates the discovery of lead
structures from ArQule’s 200 000 + chemical compound
Mapping
TM array against multiple biological targets.
ArQule has developed and reduced to practice the
automated, parallel, solution-phase synthesis of large
(103 to 104 compound sets, or arrays, of small organic
molecules. Each array contains a unique backbone
chemistry with diverse pharmacophoric side groups
attached. These arrays are created by combinatorially
reacting a serial of functionally identical but structurally
diverse building blocks to create a single compound
which is chemically analysed by HPLC and mass spectro-
metry. The compounds are logically arranged in spatially
addressable 96-well microtitre plates with a single com-
pound per well. This format yields an information rich
array where chemical structure, mass, and other proper-
ties are stored in a chemical database that is searchable
via a unique identifier. These arrays have been assembled
into a larger set of 200000 + compounds referred to the
ArQule Mapping
TM array.
Several strategies are typically employed to manage the
biological testing of a large chemical compound sets (i.e.
TM ArQule Mapping array) agmnst multiple biological
targets. Single compound per bioassay per well is the
most direct. The advantages are that no deconvolution is
required and minimal potential for ’masking’ of bioactiv-
ity exists. Single compound per bioassay fits particularly
well with the information rich nature of ArQule’s
Mapping
TM array; essentially the entire primary bioas-
say provides extensive SAR data, the negative bioassay
data also adding value for the subsequent lead optimiza-
tion activities. However, the cost of this approach is
significantly higher than the alternative strategy of
compound pooling. Pooling of between 3-10 com-
pounds/bioassay has been utilized to quickly and effi-
ciently assay large compound sets (1,2). The primary
disadvantage is the need for subsequent deconvolution of
positive readouts, the potential for masking of one
compound’s activisM by others and, specifically for
ArQule’s Mapping array the information content of
the compound set is partially lost.
In order to efficiently bioassay large-compound arrays
while preserving the integrity of the SAR information
content, we have found that multiple, parallel, high-
throughput bioassays are an attractive alternative. The
authors looked at several case examples of multiplexed
bioassays with ArQule’s Mapping
TM array and discussed
issues related to data management, prevention of readout
crosstalk and multiplexing of primary and secondary
assays.
Integrating lab automation into the drug discov-
ery process: current success and future directions
Richard H. Griey, L. L. Cummins, S. Owens, H. Sasmor, R.
Bergert, V. Mohan, E. Swayze, J. Wyatt, S. Freier, D. Ecker,
and P. D. Cook, Isis Pharmaceuticals, Carlsbad, CA, USA
Lab automation has broad impact in all aspects of the
drug discovery process and creates new challenges for
information management. The greatest impact has been
realized not for repetitive tasks, but in areas where
human skills can be leveraged effectively. The synthesis
and purification of lead compounds can be automated
using solid-phase multiwell synthesizers or by automated
purification of complex mixtures prepared by chemists.
Analysis of compound identity is performed routinely
with automated mass spectrometric or NMR services.
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Drugs are screened against a variety of biological targets
using high-throughput assay systems. Pharmacokinetic
and metabolic profiles can be generated using automated
extraction and analysis methods. While automation has
improved productivity in all of these areas, the available
information management tools are inadequate to store
and integrate the quantity of data. In the future, the time
for discovery of drug development candidates will be
shortened dramatically, as genomic information is used
to identify protein and nucleic acid targets, and lead
compounds are prepared, purified, and screened in the
automated lab.
Chasing the rate limiting step
Mark Jones, Astra Charnwood, Loughborough, UK
Bringing new drugs to the market is an extremely slow
and expensive process with a modest success rate. In
recognition of this fact, the theme for the 1990s has been
’more for less and faster’. The introduction of automated
systems has played a major role in our attempt to achieve
this goal and it has proved to be an extremely liberating
experience.
It has provided us with the opportunity to question the
things we do and why we do them to focus attention on
the rate limiting steps in the research process. We have
seldom leapt to automate our existing work practices,
instead we have explored how new technology can help
us to develop new work practices resulting in significant
improvements in productivity and quality.
It has been our experience, that by turning a ’rate
limiting step’ in to a highly efficient machine merely
serves to move the problem to another part of the
research process, consequently we find ourselves on a
seemingly endless journey of ’chasing the rate limiting
step’.
Technology transfer of automated methodsmour
early struggles
William B. Tucker, Bristol-Myers Squibb Company, Evansville,
IN, USA
In our new global economy, analytical transfer has
become increasingly important to the industry and
regulatory agencies. It has become a special concern for
the pharmaceutical industry and the FDA. Analytical
technology transfer for automated methodologies is the
next logical step in this process; however, it does present
some unique issues. As with all technology transfer, it
requires a balance of four key ingredients:
A rugged method.
Comparable equipment.
Proper training.
Mutual desire for success.
Using examples from recent experiences, the importance
of each of these ingredients, and the lessons learned were
discussed.
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Automated method validation and transfer in a
Q.C environment
Muhammad Alburakeh, Marc Rosenberg, Limin Zhang, Jon
Sadowitz and Donald Nguyen, Barr Laboratories, Pomona,
USA
Process validation requires extensive analysis to assure
the uniformity of the blend, final dosage form and drug
release profiles at different stages of the manufacturing
operation. Use of robotics to automate the testing pro-
cedures increases productivity and shortens the turn
around time for the validation results and ultimately
approval and marketing of a drug product. For the first
time we are able to successfully automate the complete
testing of a drug product to support process validation.
The dissolution, blend uniformity, content uniformity
and assay testing of a drug product was automated using
a Batch Dissolution System and a TPW II workstation.
The key to automating the testing procedures is the
validation and transfer of the methods to the QC
laboratory. This presentation covered the steps that are
necessary for the implementation of automated methods
in a QC environment.
Analytical testing alternatives,
proaches
investment ap-
Brian Hausner, Pharmalytic, Inc./Micron Technologies, Exton,
PA, USA
Today’s pharmaceutical companies are undergoing radi-
cal changes in the way they operate. This is necessitated
by greater government scrutiny, increased activity of
HMOs and other ’buying co-ops’ and the evolution of
healthy lifestyles. All factors contribute to increasing
attention to cost but also on eventual new products.
Traditional responses have been a recent wave of mergers
and moving operations to new tax havens that create
implications on a global basis, especially operationally.
Finally, numerous firms are focusing on core competency,
as they define this to mean usually drug discovery/
development and market/distribution.
Laboratory personnel need to understand their com-
panies’ strategies/objectives. What are the core com-
petencies as well as strategy drivers? These drivers
could be capacity or technology related, or simply to
shorten the product development cycle. This can be
accomplished by increasing risk by managing multiple
projects or steps within a project simultaneously. The use
of fianancial models can help support decisions based on
’intuitive’ knowledge. The types of models can be as
simple as cash flow analysis to Net Present Value and
even EVA (Economic Value Analysis). Financial models
can help balance the level of acceptable risk and goals/
strategies.
How to assign value to key drivers was reviewed using
strategic decision making programs. This information
was then used across the numerous investment alterna-
tives faced by lab personnel, using some of the previously
discussed drivers. The investment alternatives to be
considered are laboratory automation, temporary staff-
ing, use of contract analytical labs and finally internal
investment; i.e. headcount increase.Abstracts of papers presented at the 1997 ISLAR
Fully automated SPE-LC-MS
R. A. Biddlecombe and S. Pleasance, Glaxo Wellcome Ware,
Hertfordshire, UK
The authors have previously reported on the application
of the MicroLute system of solid phase extraction (SPE)
in the 96-well format for high throughput bioanalysis
using LC-MS-MS. The original system used a custom-
ized vacuum manifold located on the deck of a Packard
MultiPROBE robotic sample processor. The Multi-
PROBE performed all the liquid handling steps, but
the operator is required to manually place the collecting
plate in the vacuum manifold prior to the elution step. In
order to maximize the advantages of this approach and
overcome some of the limitations, a fully automated
standalone system has been developed. The system
consists of a Zymate XP robot, cooled storage carousel
which acts as both a warehouse for all the labware and as
a refrigerated storage for the extracts, and custom built
SPE station. The SPE station incorporate a vacuum
manifold, reagent addition strip (RAS) for rapid reagent
addition a row at a time and solvent switching valve
which allows up to nine different reagents to be used on
the system. This station allows all the vacuum steps,
conditioning, washing and elution steps to be performed
much faster and the MultiPROBE is used simply to
dilute samples, add internal standard and transfer
samples from tubes to plates. The plates containing the
extracts are returned to the cooled storage carousel to
await analysis. The acceptance criteria was to perform a
minimum of four consecutive unattended runs (384
samples) and to be capable of handling all the current
available labware (Microlute and Empore blocks).
Data were presented from several LC-MS-MS methods
using this approach and the phased development of the
system into a fully automated SPE-LC-MS-MS system
that can directly feed a PE-SCIEX API-300 mass
spectrometer and is capable of round the clock operation
was detailed.
Use of automated solid phase extraction for a
validated assay for prostaglandins in human urine
using gas chromatography electron capture nega-
tive chemical ionization tandem mass spectro-
metry (GC ECNCI MS/MS)
Clark V. Williard, Ajai K. Chaudhary, Karen M. Clements,
Robert J. White, Thomas D. Oglesby, and Paul A. Taylor,
Taylor Technology, Inc., Princeton, NJ, USA
Prostaglandins (PGs) play an important role in a variety
of diverse biochemical processes. A large number of
endogenous PG analogues have been characterized with
small structural variations. They are generally present in
extremely low concentrations. GC/MS assays have been
developed for PGs, but suffer from the presence of co-
eluting impurities which makes the measurement difficult
and irreproducible at lower concentrations. We have
modified the existing assays to develop a highly sensitive
and robust assay for PGE2 (an indicator of kidney PG
metabolism) and 6-keto-PGFl (an indicator of prosta-
cyclin production), from human urine. The lower limit of
quantitation for both the analytes is 10 pg/ml using ml
human urine. The method involves elaborate extraction
and derivatization steps. A Zymark-RapidTrace SPE
Workstation was used to automate the extraction of ana-
lytes from human urine (in reversed phase SPE mode) as
well as to purify the pentafluorobenzyle derivatives from
the reaction mixture (in normal phase SPE mode). In
addition, use of tandem mass spectrometry provides an
additional degree of specificity to the assay. The assay has
been validated following GLP guide-lines and is being
used to assess endogenous PGs production.
High throughput method development with
microtiter solid phase extraction plates for bio-
analytical mass spectrometry
John Janiszewski, Monica Swyden and Hassan Fouda,
Inc., Central Research Division, Groton, CT, USA
A semi-automated protocol for solid phase extraction
(SPE) methods development using microtiter, 96-well,
SPE plates has been developed. The technique utilizes
method development plates containing four sorbents in
groups of three across the columns of the plate. The plates
are processed using a programmable 96-well pipettor, the
Quadra 96 (TOMTEC, Hamden, CT), and laid out in
an array such that each analyte is screened across four
sorbents an four eluents in duplicate. Fast-gradient
(3 min/sample) LC/MS conditions are used to determine
recovery.
Multiple analytes (3-5) are spiked into plasma and a
100-200 ul aliquot of the fortified plasma is transferred to
the appropriate wells in a deep-well (1.2 ml) polypropy-
lene block. The plasma is diluted 1:1 with 1% phosphoric
acid prior to extraction. This sample block is then
transferred to the desk of the Quadra 96 for SPE
processing. The conditioning, load and wash steps have
been standardized and the elution volume is 100 ul. The
eluent (e.g. methanol, acetonitrile) is collected in a 96-
well polypropylene plate and combined with 50ul of
water prior to LC/MS analysis. This technique uses a
third (four columns) of the SPE plate for a given set of
analytes. In its present application three method devel-
opment experiments per plate are possible. The com-
bined setup, LC/MS analysis, and data reduction time
for a single experiment is approximately 4 h.
The optimal set of extraction conditions, yielding best
recovery, allows rapid method development for pharma-
cokinetic analysis in support of drug discovery. Refine-
ment of the SPE conditions are sometimes needed to
extend the limit of quantitation. We have tested numer-
ous (> 100) compounds using this approach, 90% had
recovery of 70% or better and 95% had recovery better
than 50% from plasma. Experience with method devel-
opment technique using both the 3M Empore and
Porvair style microtiter solid phase extraction plates
was described.
High throughput sample preparation for LC-MS/
MS bioanalysis using 96-well SPE plate and robot
H. Simpson, D. Buhrman, R. Burton, J. Newton and D. Wu,
Sanofil Pharmaceutical, Inc., Malvern, PA, USA
The 96-well solid phase extraction (SPE) plate offers a
55Abstracts of papers presented at the 1997 ISLAR
rapid preparation approach for the analysis of drugs and
metabolites in biological matrices, based on simultaneous
extraction of 96 samples. In addition, the SPE plate
operation can be automated by robots, further increasing
productivity while reducing labour cost. In this study, a
thin disk (membrane) containing chromatographic pack-
ing material immobilized within polytetrafluoroethylene
carrier (Empore
TM disk) has been incorporated into the
96-well plate as the SPE sorbent. The small bed volume
in the disk plate resulted in small elution volume (75-
200 pl), allowing direct injection of the elution fraction to
LC-MS/MS at the end of the sample preparation; and
significantly improved sample-to-sample reproducibility
due to reduced channelling effect on the disk. The
performance of the disk plate was characterized in this
presentation by compounds of wide range of basicity to
represent pharmaceutical agents. Optimal conditions
were evaluated based on the volume, flow rate, vacuum
control, mass recovery, potential clogging, use of acid to
elute basic compounds, etc.; the results were presented.
The automation of the disk SPE plate operation was
accomplished by a modified MultiPROBETM 204 DT
robot. A computer controlled solenoid valve was incor-
porated into the robot to control the flow rate of solvents
with varying viscosity. A software procedure, ’Check
Well’, was developed to search for clogged wells based
on liquid sensing, to avoid overfilling of the wells and
potential contamination of the adjacent wells. The
sample preparation using 96-well disk plate by a robot
adds enormous value to a bioanalytical lab. The data
obtained from several Sanofi compounds (for example,
SR 46559, SR 31747 and SR 46349) were presented to
demonstrate the utility of the technology. All these
compounds were validated to the minimum quantifiable
level of 0.2 ng/ml or lower. The typical accuracy and
precision were < 5% either within or between runs. The
validated methods have been successfully applied to
clinical sample analysis. The throughput and assay
performance were reported.
Towards comprehensive combinatorial chemistry
information management
j. Christopher Phelan and U. Josh Patel, Arris Pharmaceutical,
South San Francisco, CA, USA
Combinatorial chemistry creates a need for new methods
of data handling that allow tracking of synthetic pro-
cedures, precursors, product structures, and analytical
and assay data for thousands of compounds per months.
The throughput needed requires that human interven-
tion in the data handling be minimized. Maintaining
accuracy of the data with respect to physical reality
requires that the data path be tightly correlated with
the physical production of actual combinatorial libraries.
The authors described progress in addressing these issues
in a context where chemistry development, production,
and analysis of combinatorial libraries were performed by
separate workgroups. Data structures designed to repre-
sent the actual steps in a combinatorial synthesis includ-
ing reactions, protocols, precursor sets, and physical
layouts were present. Design and implementation of
software on multiple platforms to handle these data
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structures concurrently with the actual synthesis of
combinatorial libraries were discussed. Goals included
automated generation of robot operating instructions
from synthesis specifications, automated generation of
product databases including tracking information from
actual synthetic procedures, subsequent incorporation of
analysis and bioassay data into these databases, and
quality management issues for the various stages of this
process.
An integrated system of data generation, analysis,
and management for use in an HTS environment
Mark J. Suto and Laura J. Schove, Signal Pharmaceuticals,
Inc., San Diego, CA, USA
A key component to the success of any drug discovery
programme is the integration ofHTS and combinatorial
chemistry with database management and molecular
diversity systems to yield an efficient and cost-effective
method of organizing chemical information and biologi-
cal data. At Signal, we initially loaded the HTS data into
familiar applications such as Microsoft Excel, Hyper-
Card, and local ISIS/Base databases, but their capacities
were quickly overwhelmed by the immense amounts of
data. We immediately saw the need for an integrated,
efficient HTS information management system. Using
MDL’s SCREEN and ISIS/Host, we linked Oracle-
based biological data and corporate identifiers with
structural and catalogue information for data storage of
biological and management. In addition, we integrated
into this system Tripos’s Chemical Diversity management
suite of modelling software. The integration ofHTS and
combinatorial chemistry for rapid data generation, mol-
ecular diversity techniques for data analysis and evalua-
tion of samples to be tested, and database management
systems for the integration and storage of biological and
structural data was achieved. This approach provides
Signal with a comprehensive, efficient, and cost-effective
programme for the discovery of novel therapeutics. In the
future our biggest challenge information management
will be in how we administer and optimize data as we
work to validate leads and develop them into drugs. The
success ofmany companies in facing this task will depend
not only upon solid scientific expertise, but on a will-
ingness to adapt and change both traditional views of
drug discovery and methods for communicating and
handling results.
A robot’s story: from take down and move to
operational in two weeks--fact or fiction?
Allison Manners and Howard Balter, Eli Lilly Canada Inc.,
Scarborough, Ontario, Canada
Today’s laboratories are focusing more and more on
automation to either increase their analytical capabilities
or to utilize scientists’ resources elsewhere in the testing
facility. A substantial amount of time and effort is needed
to establish automated programmes and to validate the
operation of the robotic systems. Therefore, once a
robotic system is fully functional and validated, the last
imaginable situation would be to dismantle the robot and
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environment in the pharmaceutical industry, these types
of events are a regular occurrence. Moving an automated
system should not be something to fear.
In late August 1996, the Lilly Analytical Research
Laboratory now located in Scarborough, Ontario,
Canada, moved locations. Prior to the move, two auto-
mated systems were fully validated and in routine use
running potency, related substance, and preservative
assays for a variety of pharmaceutical dosage forms. By
mid-October of the same year the systems were once
again fully validated and operational in the new facility.
The basis of this presentation was the steps implemented
to make the transition between sites as seamless as
possible and to share the learning acquired during the
move. The need for appropriate planning, organization,
and resources was discussed, as well as some unique short-
cuts.
Enhancement of sample preparation through new
technology
Jay Desai, Ortho-McVeil Pharmaceutical Corporation, Raritan,
vy,s
By enhancing the existing robot capabilities with new
technology the Quality Assurance Analytical Laboratory
was able to achieve its new cycle time initiatives for
sample throughput. Initially, the mission of the QA
Lab was to reduce cycle time for Ortho Novum content
uniformity testing. With this primary goal in mind, we
looked at the robot preparation time and testing pro-
cedure. We knew that we would have to reduce our
sample preparation time. A decision was made to
upgrade the robot by modifying its configuration. The
following changes were made:
A new over the balance reagent addition and tablet
addition station.
A pipetting station.
An EasyFill vial filling station.
The method was scheduled using Zymark’s System
Productivity Software package.
With these upgrades the cycle time was reduced signifi-
cantly.
Managing laboratory automation: a case study
into the automation of a high volume dissolution
laboratory
Patrick Drumm, Novartis, Summit, NJ, USA
In February 1996 as a result of both increased laboratory
demands and our inability to add staff, we were forced to
look to automation to fulfil our future objectives. A quick
survey confirmed that our centralized dissolution labora-
tory was in fact the best place to start. A team was formed
composed of both automation and laboratory chemists.
They were charged with presenting to management a
defensible automation plan and then with the more
difficult task of implementation and validation.
This paper discussed the key elements of the laboratory
automation process. In particular, it focused on:
A team-based approach: It is essential that the right
people be brought together, with the guidance of
management, to solve these difficult problems.
Solutions developed from within, although not
always possible, should be the goal. These internal
solutions are the most likely to succeed in the long
run, since they have the full commitment of the lab
group.
A sound automation plan: This important area
includes tools such as process flow diagrams and
cost benefits analysis. In addition, considerable
research is necessary to form a complete list of alter-
native solutions.
Carefully assigned objectives, responsibilities and
accountabilities: An individual ’champion’ should
be selected for each automation project however
minor. These individuals should be given adequate
resources (time) to support their project.
Equivalence to the existing validated method: This
is the essence of validation and represents the single
most powerful argument for acceptance of the auto-
mated method.
Data manufacturing: transition to an industrial
mindset for laboratory automation
James M. Gill II, Glaxo Wellcome, Inc., R TP, 2VC, USA
The introduction of high throughput screening as a tool
for discovery pharmaceutically useful compounds has led
research to shift from work practices grounded in the
craftsmanship of science to processes based in manu-
facturing. This change has occurred for two reasons.
First, industrial scale automation is required to handle
the increase in the volume of assays required by HTS.
Second, and perhaps most important, just as industry
must minimize the cost of each widget produced, the
success of HTS depends on optimizing the value of each
data point produced. The starting point for optimizing
work lies in correctly capturing work practices in an
algorithmic or rule based form. Once practices have been
captured they can be quantitatively analysed and opti-
mized. The industrial revolution in lab automation has
also broadened the scope of automation requiring analy-
sis of the cost of processes across many independent
systems. Our group is using techniques borrowed from
industry such as a statistical process control, automation
quality control, statistical experimental design and im-
plementing low function but highly parallel workstations.
The use of those techniques in the context of the move
from 94 to 384 well assays was discussed.
Adapting PCS to non-Zymate architectures
Dinesh S. Thakur, Vincent W. Chen and Kirk J. Leister,
Bristol-Myers Squibb Company, Syracuse, NY, USA
Bristol-Myers Squibb has developed and implemented a
microplate assay system that utilizes extension compon-
ents for a modified version of the Productivity and
Communications Software (PCS from Zymark Corpora-
tion) for scheduling and coordinating peripheral hard-
ware. This System hardware includes a Sagain ORCA
robot, a RapidPlate-96 Workstation, two Tecan Genesis
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Liquid Handling Workstations, a Zypettor, two Zymate
XP robots (one serving as the primary robot for PCS and
the other a part of an on-line reagent preparation
station), and a custom GUI front-end.
The ORCA is used as a peripheral component and is
controlled by an extension component to PCS using DDE
as the interprocess communication mechanism. The
RapidPlate-96 Workstation is controlled as a peripheral
component via NetDDE in order to be used as a stand-
alone peripheral. The two Tecan Genesis workstations
are controlled by an extension component that coordi-
nates the tasks performed by these workstations. The
Zypettor and the two XP robots are controlled via the
System V controller by the modified PCS. This system
uses a front-end with custom interfaces to collect informa-
tion and create a dynamic run-time schedule.
Typically, PCS supports Zymate architecture where one
robot coordinates all peripheral hardware and additional
robots are connected via local controllers to the main
controller. Laboratory Unit Operations (LUOs) per-
formed by the robots connected via local controllers are
addressed as batch operations by PCS. This system uses
the ORCA to get and put labware from the Tecan
Genesis Workstations and the RapidPlate-96 Work-
station, tasks typically not addressed as batch operations.
The architecture implemented for the resolution of run-
time variables collected by the custom front-end, the
coordination of ORCA tasks, Tecan Genesis liquid
handling workstations and the RapidPlate-96 work-
station with the extension components were discussed in
this presentation.
Specification testing robotman automated analy-
tical laboratory
Perry Hailey, Pfizer, Sandwich, Kent, UK
While laboratory automation has grown in complexity,
there are significant technical and business benefits in
employing a modular approach when selecting instru-
ments for automated systems. Rather than use a single
complex instrument to perform a variety of tasks, a
modular approach separates the various tasks among a
number of specialized robotic units. Each of these instru-
ments is designed for a specific task, often built by
multiple vendors, and is capable of independent opera-
tion from the other modular units within the overall
robotic system. This modular approach has significant
advantages in that each unit can be operated indepen-
dently by analysts, the failure of one modular component
does not effect the overall performance of the automation
design and also allows for opportunities to develop and
modify the system as requirements change. Associated
with the modular approach to instrument design is a
modular approach to software. Software such as Lab-
View or Visual Basic supports the concept of modular-
ization, especially Labview which allows the construction
of small modular code. It is important when developing
to select a stable and secure operating system and
Windows NT satisfies these criteria.
The overall concept of the specification testing robot is to
deliver a robotic system capable of performing the
majority of the testing requirements contained within a
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typical specification for the testing of drug product
batches into an integrate system. The modular approach
seeks to break the overall testing regime into component
parts and this was described. The importance that IT
plays in delivering the system was also discussed.
Development of workstations for filtration and
purification of samples prepared by automated
synthesis
David A. Rudge and Mandy L. Crowther, Zeneca Pharmaceu-
ticals Ltd, Maccleeld, Cheshire,
Automated organic synthetic chemistry has been under-
taken in the Robotics Laboratory at Zeneca Pharmaceu-
ticals since 1992 using Zymate
TM XP Laboratory
Robots. Isolation of products by a variety of procedures
for the test in biological screens from a wide range of
chemistries has been essential. The option to filter solid
materials, from reaction mixtures and, at times to purify
the products produced has required the manufacture of
new modules to accommodate these demands.
Constant development has been undertaken in the area
of filtration due to the increased volumes utilized on the
synthesis robots. Systems have now been designed to
allow off- and on-line chromatographic purification of
samples up to g using Mega BondelutTM Chromato-
graphy cartridges.
The authors’ experiences in developing these two pro-
cedures for product isolation were described.
Development of an automated chromatography
system
Gary C. Walter, Clare Elliott and Karen F. Higgins, Zeneca
Agrochemicals, Bracknell, Berks, UK
With the development of efficient systems for robotic
syntheses, sample purification has become a bottleneck
in the process of production ofnew chemicals. This paper
described the development of an automated chromato-
graphy system that is capable of processing 40 samples in
parallel. The system can provide gradient elution and has
the ability to change the gradient profile. Ten fractions
are collected for each sample and are then analysed by
thin layer chromatography using a Gilson liquid hand-
ling robot. A description was given of the way in which
the new system improves productivity and turnaround
time in comparison with existing equipment.
The future of compound distribution at Glaxo
Wellcome
Brenda Johnson Ray, Glaxo Wellcome Inc., Research Triangle
Park, NC, USA
Compound distribution for discovery research has
evolved so much over the last several years that a set of
standard operations becomes obsolete almost before it is
implemented. The ever changing requirements for
screening have left the door open for new sample formats,
container types, automation, storage, barcoding, inven-
tory tracking and even the amount of compound re-
quired for testing. When will these rapidly changingAbstracts of papers presented at the 1997 ISLAR
requirements settle down, evolving to a set of best
practices for compound distribution and screening? The
answer doesn’t seem to be in the foreseeable future. This
presentation outlined how the Discovery Compound
Distribution group at Glaxo Wellcome has advanced its
sample handling practices so far, and continues to plan
for the uncertainties of the future.
Documentation and validation activities in the
development of a robot system for the testing for
sterility
Elisabeth Averdam and Klaus Haberer, Hoechst Marion Roussel,
Frankfurt, Germany
A particularly important function of the Microbiology
Department of Quality Operations is to minimize calcul-
able risks and ensure that test parameters are as constant
as possible. In the test for sterility, contamination by
means of, for example, manual intervention must be
prevented. The automation of this test by the introduc-
tion of robots could greatly contribute to the aforemen-
tioned goals. The suitability of such robots must be tested
and documented with respect to their subsequent appli-
cation in the strictly regulated pharmaceutical field. The
robot must comply with a large variety of legal guidelines
and technical standards, ’in-house’ standards laid down
by, for example, engineering or quality assurance depart-
ments, as well as technical recommendations and guide-
lines laid down by scientific societies.
To facilitate the validation of the complex computerized
system in compliance with the various requirements as
mentioned above, detailed validation protocols were
purchased with the robot as a framework for the doc-
umentation. Only by cooperating closely with the com-
panies involved was it possible to successfully bring about
the necessary new developments in the field of technical
accessories. A change control procedure was used during
assembly of the robot as the PyTechnology system
originally used had to be changed to a linear-axis
system. The milestones of the project include design
qualification, the works approval check lists, installation
qualification, operation qualification and performance
qualification which are documented with corresponding
protocols.
This paper dealt with the structure of the formal docu-
ments integrated in the overall documentation together
with the concept, the manufacturer’s specifications and
validation plan. Requirements and first experiences up to
and including operation qualification were presented.
A fully automated robotic solution for QC HPLC:
A real life story about justification, implementa-
tion and operation
The Brooklyn NY site of Pfizer Inc. is integral for the
scale-up and manufacturing of newly developed products
to supply pharmaceutical samples to the sales force as
soon as the produce receives approval from the FDA.
Several manufacturing steps are required to provide
modern pharmaceuticals to market, and hundreds of
analytical methods are employed to ensure product
quality. Quality control is a partner with manufacturing
and research, and is responsible for gathering data to
support the manufacturing, packaging and stability of
products. The preferred method for assay and uniformity
characterization of the manufacturing process utilizes
high performance liquid chromatography (HPLC).
Representative samples are received from the various
manufacturing steps including raw materials, mixed
blends, tablet cores, and finished goods.
The Brooklyn Quality Control unit tests approximately
80000 samples per year using HPLC. Testing usually
involves four steps: sample preparation, chemical analy-
sis, result generation, and data review and approval.
Over the years, instrumentation has been improved for
chemical analysis, and data acquisition systems have
become proficient in processing data for result genera-
tion. Sample preparation is usually the most time-con-
suming testing component, and due to the repetitive
nature, can lead to testing errors. Robotic applications
are currently available to assist laboratories to automate
sample weighing, disintegration and extraction, dilution,
filtration, injection onto the HPLC system, and result
generation. Automation’s individual tasks are seldom
fast, but when concatenated, can provide more efficient,
accurate, and precise data. Additionally, environmental
benefits can be realized due to reduced solvent consump-
tion and emissions, and the skilled analyst can be freed of
tedious work to perform more complex tasks.
The justification, implementation and operation of a fully
automated robotic system were discussed. The criteria for
selecting automated applications, appropriate steps to
validate the robotic system and analytical methods, and
potential advantages and disadvantages were presented.
Image capturing in high throughput systems and
global fingerprint monitoring
TM automated visual
Go/No-Go decisions
Richard P. Gill and Richard H. Selinfreund, Lion Laboratories,
Old Saybrook, CT, USA
The standard high throughput system (HTS) generated
reams of numerical data that must be processed and
eventually interpreted by operators. HTS operations
require complex initial start-up calibrations, material
pre-qualification, on-line process control, go/no-go deci-
sions and final process analysis. Using numerical analysis
to control HTS significantly slows down operations. In
fact, numerical analysis control points can cause incorrect
go/no-go decisions under HTS speeds. Utilizing the tech-
nique of Real Time Image Capturing allows the HTS
controller and operator to make significantly more
accurate go/no-go decisions.
Real Time Enhanced Image Capturing is possible using
computerized digital imaging systems built into the
microplate scanner units. The digital image is then
automatically analysed by software that processes images
and numerical data. Standard Images can be stored in an
optical database that provides the baseline for calibration
and process control. Standard optical images provide
optical fingerprints. HTS standard images can be rapidly
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compared to on-line images to make improved go/no-go
decisions. Furthermore, final process analysis of numer-
ical data can be coverted to optical images using Global
FinerPrint Monitoring SoftwareTM. Ultimately, optical
image analysis makes the task of operating and analysing
HTS results simple and accurate. The paper described
HTS process control using optical imaging and a process
to automatically convert numerical data to useful optical
images.
Diogenes at Delphi: evaluating software for high
throughput screening
John Morin, Jaweed Ashraf, Fred Immermann, James La-
Rocque, Fernando Ramirez, Linda Heydt, T. C. Ramaraj, Imad
Mansour, Mariya Gazumyan, Michael Greenstein, Ian fore,
Dave Vanderbrooke, Sheryl Jeffas, Gary Kuehnlenz, Diana
Adams, Ronald McCaully, John Babiak, Wyeth-Ayerst Re-
search, Pearl River, 2VY, USA
Timely data management is a significant challenge for
most high throughput screening groups. Our data man-
agement procedures have evolved through many stages
over the years. We have progressed from laboratory
notebooks and other paper trails to ad hoc use of
Microsoft’s EXCEL and Access and through a short
succession of customer systems developed by our cor-
porate research computer departments. Our current
corporate system with a custom desktop application for
plate processing and an OMNIS and ORACLE client/
server database application, provides most of the func-
tionality we need at the moment. Proprietary systems,
however, tend to be vulnerable to loss of key personnel
and to shifts in allocation of corporate resources. It is
difficult to justify continuing development of functions
that might be outsourced. In order to meet the data
management requirements of our rapidly increasing
throughput and decrease our reliance on internal com-
puter programming resources for further software devel-
opment and maintenance, we have evaluated several
commercially available high throughput screening soft-
ware systems This process was described.
Accelerated structure profiling using automated
LC/MS and robotics
Jeffrey L. Whitney, Robyn A. Rourick and Kevin J. Volk,
Bristol-Myers Squibb Pharmaceutical Research Institute, Prince-
ton, 3?J, USA; Saul Fink, Edward H. Kerns, Mark E. Hail
and Mike S. Lee, Bristol-Myers Squibb Pharmaceutical Research
Institute, New Brunswick, NJ, USA
The pharmaceutical industry is currently undergoing
initiatives aimed at accelerating the drug discovery,
development and registration cycle. These initiatives
have emphasized several key areas such as enhancement
of productivity, early initiation ofprogrammes, shortened
time lines, parallel operations and faster go/no go
decisions in an environment where prospective drug
candidates and new chemical entities are expected to
increase 10-fold and three-fold, respectively. Clearly,
greater amounts of information produced in a fraction
of the time are required to meet these demands. Analy-
tical analyses provide critical insights throughout all
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segments of this cycle. Advanced analytical technologies
based on standard high throughput methods are a key
factor in producing this information and meeting these
challenges. LC/MS is one such emerging technology that
is transforming the pharmaceutical industry by providing
unparalleled structural information to a wide range of
analytical problems in reduced time periods.
Traditional structure analysis involves several time and
resource intensive steps, such as scale-up, extraction,
fractionation and detailed multi-technique spectroscopic
analyses. By coupling HPLC and Tandem Mass Spectro-
metry, the typical bench-scale approach is transferable to
a single on-line structure profiling ’engine’. In this
manner one can take advantage of high sensitivity,
selectivity, speed and ’universal’ application capabilities
inherent in these technologies. However, simply integrat-
ing these two powerful techniques is not enough. Elim-
inating custom method development through the use
of standard methods and removing tedious manual
protocols with automation are required to reduce the
resource-intensive nature of LC/MS and LC/MS/MS.
Additionally, automated analysis and processing
methods must be combined with electronic sample track-
ing and results’ communication to prevent information
overload. With this approach over 80% of our projects
can be addressed with a single set of methods. Productiv-
ity increases of 3- to 5-fold over traditional approaches
have been benchmarked.
Applications of our LC/MS and LC/MS/MS-based
structure profiling approach include metabolite identifi-
cation, natural product elucidation, impurity/degradant
identification and biomolecule characterization. LC/MS
information from these analyses (e.g. retention time,
molecular weight, substructure, etc.) is assembled into
structure profile libraries which provide a reference for
each drug candidate, linked by common standard par-
ameters. These libraries accelerate the identification of
’in-process’ drug candidates, as well as their respective
impurities, degradants and metabolites. Structure li-
braries are also proactively produced early in the re-
search process to predict chemical information which
may provide valuable insights downstream in the process.
These predictive profiles are produced by analysing
samples of drug candidate exposed to various chemical
environments, e.g. heat, light, acid, base, peroxide, etc.
Currently the rate-limiting steps in the predictive profile
are sample production and introduction to the LC/MS
instrument and interpretation of data. Initiatives are
underway to automate the sample preparation, incuba-
tion and LC/MS injection steps on a Zymate XP plat-
form equipped with several ’off-the-shelf’ Zymark
components. Our strategy centres around developing
an investigative robotics method development station
which will integrate seamlessly with our existing structure
profiling methodologies. In this manner, the robotics
platform will add an additional dimension, automated
sample production and preparation, to our structure
profiling ’engine’. Examples were shown illustrating the
LC/MS-based structure profiling methods and ongoing
applications of automated predictive profiling and ro-
botics.Abstracts of papers presented at the 1997 ISLAR
Developing a flexible architecture for the Tecan
Genesis liquid handling stations
Dinesh S. Thakur, Vincent W. Chen, Robi L. Banerjee,
Matthew G. Holt and Kirk J. Leister, Bristol-Myers Squibb
Company, Syracuse, gVY, USA
Liquid handing stations have become an integral part of
automated assays based on microplate technology. The
hardware on these stations is amenable to transferring
liquid in an accurate and precise manner. Integration of
these stations into automated systems can be addressed in
either of two ways:
Develop analytical methods in the software supplied
by the vendor of these workstations.
Develop component software that provides com-
plete control of the hardware through a defined
interface for analytical methods development.
The first and more common approach for developing
automated systems is to use the vendor supplied software.
Once the analytical method is developed, the software
controlling the automated system invokes this pre-pro-
grammed analytical method at run-time. This approach
provides the fastest solution since the integrator does not
have to deal with instrument specific details of the
workstation.
The second approach is to develop component software
that provides complete control of the workstation. This
approach allows an integrator to program the analytical
method in the software that controls the automated
system. This is made possible by exposing complete
functionality of the hardware of the liquid handling
station through a defined interface. The upfront invest-
ment in development time provides greater flexibility for
control of the liquid handling station through seamless
software interfaces.
Bristol-Myers Squibb has developed a flexible architec-
ture for the Tecan Genesis Liquid Handling Station that
allows for complete control of the workstation through a
defined interface. This architecture is not specific to any
particular method; it is re-useable with many applica-
tions and integrates seamlessly with the software that
controls the automated system. It allows for the devel-
opment of systems with single interface for all peripheral
hardware. This architecture is based on the principles of
Object Oriented Design and utilizes the application
programming interface (API) exposed by a library
supplied by Tecan AG. Furthermore, this architecture
addresses error handling and recovery for the Genesis
workstation in greater detail than that provided by the
vendor software. The specifics and the utility of the
architecture implemented were discussed in this presenta-
tion.
Automation of pH, viscosity, and colour meas-
urements for liquid detergents
Alp Uray and Laren Addabbo, Corporate Technology Center,
Colgate-Palmolive Company, Piscataway, NJ, USA
In the manufacture of liquid detergents, consistent and
stable pH, viscosity and colour are critical to consumer
acceptability. These parameters (viscosity, pH, and
colour) are frequently testing during a product’s devel-
opment cycle as key indicators for product stability. Once
established, these parameters can then be monitored to
assure consistent quality when a product formula is
moved into production. With the use of an articulated
robotic arm, integrated bar code labelling system, custom
software and customized distribution system using flow
cells, a system which automates multi-sample measure-
ment of pH, viscosity, and colour for liquid detergents
has been built. This paper discussed the development of
the system and results to date.
Automated dye analyses using the Zymark Bench-
Mate II workstation
Rhonda. Peisch! and Marie Sabo, Clairol, Inc., Stamford,
USA
Working as part of a technology service group (Analy-
tical Research & Services) provides not only many
technical challenges, but also significant challenges to-
wards managing priorities and maintaining an adequate
service level for all of our customers. Laboratory auto-
mation has played a key role for the chromatography
section of the Analytical Research and Services group at
Clairol by increasing productivity and increasing the
number of requests that can be handled at the very same
time. Simple laboratory automation such as HPLC
autosamplers and programmable instrumentation have
been easily introduced and utilized to conduct many
unattended analyses throughout the evening hours.
Automated workstations or combinations of automated
instrumentation are also being linked together to aid in
multi-tasking chromatographic projects. Some examples
of automated workstation applications currently being
employed in the chromatography labs include (1) pre-
paring product development stability sample solutions
using a Zymark BenchMate II Workstation, spotting
these solutions on TLC plates using a CAMAG ATS3
(automatic TLC spotter), reading the colour of the spots
using a Shimadzu csg000U Spectrodensitometer, and
then analysing the data using a computer program; (2)
preparing sample solutions for safety support study(s)
and transferring solutions to HPLC vials using a Zymark
BenchMate II Workstation, analysing solutions by
HPLC or UV/Vis; and (3) preparing processing or
production troubleshooting sample solutions using a
Zymark BenchMate II Workstation evaluating solutions
by qualitative or quantitative TLC.
Considering the complexity and diversity of samples and
requests the chromatography group continues to be
challenged with on a daily basis, automation will con-
tinue to play a key role. This presentation demonstrated
some of the automated workstations and applications in
use in the authors’ laboratory and introduced some new
automation ideas.
TM A Windows based interface for the Zymark
TM
robot
Stephen Dokoupil, Helene Curtis, Inc., Rolling Meadows, IL,
USA
The development of a laboratory robotics application
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which connects several independent components can be a
difficult job for the systems developer. Monitoring and
visualization of the process activities can be simplified
when efficient programming tools are used. This paper
described the development of a user front end that was
developed for use with the Zymark XP robot. The
software operates under Windows 3.1 and was developed
with LabVIEW, a programming language specifically
designed for use in laboratory automation and control
applications.
The software collects data from the robot as it is being
generated, prints and logs the data to a data base file.
The software features an intuitive graphical interface that
allows manual control of the robot with mouse. When
error conditions occur, the software notifies the user and
allows error recovery. When testing is completed, the
software will instruct the robot to put samples away and
shut itself down.
This paper discussed the basic design of the software,
with emphasis on the robot communications module, the
user front end, and the logic flow needed for manual
robot control and error recovery. The paper also dis-
cussed the advantages of programming with LabVIEW
and reasons for developing in the Windows environment.
The use of robotics in a cosmetic microbiology
laboratory
Steven F. Schnittger, Estee Lauder Companies, Research &
Development, Melville, NY, USA
The preservative challenge test is a method used to
determine the efficacy of a preservation system in a
cosmetic formulation. The method of testing is a labour
intensive, repetitive task which consumes many hours.
Product testing entails a large volume of samples which
are analysed repeatedly under the same conditions and
protocol. For this reason, an automated robotic system
was developed to perform this testing and to free the
cosmetic microbiologist to perform more meaningful and
creative tasks.
Two hundred and fourteen different formulations total-
ing 1039 samples were evaluated comparing the auto-
mated robotic system to the manual plate count method
of testing. The samples were comprised of make-ups,
shampoos, conditioners, oil in water emulsions, mascaras
and powders. The selection of micro-organisms tested are
similar to those recommended by the CTFA Guideline
for the Preservation Testing of Eye Area Products. The
results showed that there was a greater than 98%
correlation in results when comparing the Automated
Plating System to the Manual Method of Testing. It has
also been determined that the robot can save between 2-
3 man hours per day.
The unattended sample preparation of the robot permits
testing to continue beyond the normal workday of the
job. By programming the robot to run 24 h per day, the
microbiologist or technician is able to perform other
functions in the lab. It also accommodates an increase
in the workload of the lab, thus improving the through-
put of the lab without additional personnel.
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Multi-component assembly and rapid generation
of small molecule libraries on solid support
John Perumattam, Sarvajit Chakravarty, Sandhya Suravajjala,
Scios Inc., Sunnyvale, CA, USA
A simple and general approach to the synthesis of chemi-
cal libraries based on a universal anhydride template
allows the preparation of large number of compounds.
Various cyclic/acyclic amines, primary/secondary
amines, differentially protected bifunctional amines were
used as nucleophiles to react with anhydrides. The free
carboxylic acid generated was then coupled with various
amines. The facile and rapid generation of this multi-
component assembly can be accomplished on solid sup-
port.
The design, synthesis and automation of a 500 000
compound library
M. Adam, M. Allen, S. Andrie, J. Blake, L. Charles, C.
Courtney, K. Estep, S. Goldstein, M. Gross, P., Kowalczyk, J.
Levine, S. Liras, J. Lorch, C. 2Veipp, D. Phillips, S. Robinson,
E. Roskamp, D. Smith, R. Spencer, L. Stephens-Stramiello, T.
Stilwill, and G. Young, Pfizer Central Research, Groton, CT,
USA
This presentation covered the library, automation design,
and data management of a 500K library of druglike
molecules. Library design includes desired parameters
of the products, monomer selection, reaction verification
and actual synthesis. Automation design encompasses
equipment to handle porous tubes, error checking, soft-
ware and reaction apparatus. A relational database was
used to determine the path of each tube, to track the
tubes and for sorting at each synthesis step. Finally, the
lessons learned were discussed.
Automated synthesis is necessary.., but how to
get started: fully or semi automated?
Sigfried Brandtner and Helmut Buschmann, Grunenthal GmbH,
Stolberg, Germany
One of the essential goals of pharmaceutical chemical
research is to find new active compounds. The synthesis
of a screening compound requires substantial experi-
mental effort on the part of the practicing chemist.
Success in this exploratory part of research is often
correlated to the number of molecules that have been
synthesized, but organic chemistry is one of the most
labour-intensive sciences. Combinatorial chemistry is one
of the important new methologies developed by aca-
demics and researchers in the industry to reduce the time
and costs associated with producing effective, market-
able, and competitive new drugs. As with traditional
drug design, combinatorial chemistry relies on organic
synthesis methologies. The difference is the scope--in-
stead of synthesizing large amounts of a single compound,
combinatorial chemistry exploits miniaturization and
automation to synthesize large libraries of compounds.
The combination of high throughput screening and high
throughput parallel synthesis of organic compounds has
great capabilities in identifying novel drug candidates of
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meet the increasing demands of high throughput screen-
ing for test compounds, we have been developing an
automated workstation approach to have automation in
place when it is necessary, not only when it is nice to
have. We designed and built our automation tools the
way in which organic synthesis of single compounds is
carried out in the laboratory with a minimum of mod-
ification to the chemical method of reaction preparation,
execution and isolation of the desired product. The
design, development and realization of a multi-work-
station approach was presented.
Radio frequency encoded combinatorial chemis-
try-combining the advantages of parallel syn-
thesis and the split and pool technique
Anthony W. Czarnik, IRORI Quantum Microchemistry, La
Jolla, CA, USA
The synthesis of small molecule libraries of the order of
1000 to 10000 members will soon be a standard job
expectation in the medical chemistry laboratory. In
addition to the obvious equipment requirements for
miniaturization and chemical compatibility, the sheer
numbers involved demand that reaction vessel handling
become automated. Miniature radiofrequency memory
tagged reaction vessels that are readable electronically
are being developed. Work has focused on the association
of tags with two different polymeric supports for syn-
thesis: loose resin held in a rigid, porous can (Micro-
KanTM) and an inert tube onto which synthesis resin is
grafted (MicroTubeWM). In most instances, the tube
approach appears to yield advantages in reaction agita-
tion and washing steps, as well as in the purity of final
products. The movement of reaction vessels can occur at
many stages of the library synthesis process: initial read-
ing of all tagged vessels, placement of tubes in initial
reaction pots, washing, movement to subsequent reaction
pots, and cleavage of products from the reaction vessels.
In this presentation, the author described work using a
fully manual system, as well as the development of an
automated sorter capable of moving thousands of reac-
tion vessels to individual reaction pots.
Excel templates for reporting analytical results
Alger Salt, Glaxo Wellcome, Research Triangle Park,
USA
The author uses templates created in Microsoft Excel to
report results and to process data collected from analy-
tical instruments. Excel allows the author to perform
calculations, create the reports, and export results to
larger systems such as our VAX-based stability data
base. Two examples, both for processing dissolution data,
are MDUV and DisCor. MDUV is a software tool that
improves the efficiency of transferring and processing
data collected by the MultiDose workstation. DisCor
applies mathematical corrections to dissolution profile
data to compensate for the medium and analyte removed
for off-line analysis. Both applications were described and
demonstrated.
Good development practices common to regulated
and non-regulated data management systems
J. Macdonell, Taratec Development Corporation, Bridgewater,
Standards and procedures developed to insure the in-
tegrity of systems and data utilized in the regulated
environments offer value and controls that can be
extended to non-regulated environments.
Various GxP regulations require established methodolo-
gies and practices in the development, implementation,
and operation of regulated systems. It is acknowledged
that these agreed upon methodologies and practices also
achieve business value in terms of reduced risk, controlled
development, advanced user knowledge of the systems
capabilities, and forecasted cost control and return on
investment.
This presentation discussed how guidelines established to
meet FDA requirements can be effectively and efficiently
applied to the development of other systems. These
guidelines provide a known starting point and baseline
under which all systems can be implemented. Should
users need to utilize such systems in a regulated environ-
ment the known steps to a validated system are clear and
achievable. Further, the established controls lead to
better and more user focused systems. The lessons learned
regarding what works well and what areas are of greatest
concern were explained.
Data management industry task force summary
Matt Citardi, Barr Laboratories, Pomona, gVY, USA
An Industry Task Force on Automation and Data
Management was formed in April 1997. The group
consisted of representatives from the pharmaceutical
industry and was facilitated by Zymark’s PDF Team.
The group met to discuss current issues relating to
laboratory automation and data management. Use of
automated sample preparation instruments is known to
create a new bottleneck in laboratory workflow. Auto-
mation and robotics can alleviate the backlog of samples
created by sample preparation and analysis requirement.
In the majority of situations, manual labour is required
to review and transfer the large amount ofdata generated
into a results reporting program. Through formal inter-
views and interactive discussion the common constraints
and problems with this approach were identified. The
Task Force developed potential solutions to the prob-
lems, focusing on technologically feasible solutions that fit
within the corporate data strategies. The Task Force
findings were presented and followed by a panel discus-
sion.
Ultra-high-throughput screening with 1536 wells!
Where is the physical limit in well size?
G. Knebel, Greiner Labortechnik GmbH, Frickenhausen, Ger-
many
The increasing demand for miniaturized assays for high-
throughput screening has been the driving force in
63Abstracts of papers presented at the 1997 ISLAR
designing 384-well plates with the same footprint as a 96-
well plate. The 384-well plate incorporates a quadruple
higher well density with a one-half well to well spacing of
4.5 mm. The decision to make square instead of round
wells has reduced total volume to a third (120 gl); routine
working volume is 30-90 lal.
The skill and efforts of technical staff has resulted in
further miniaturization. Greiner has developed a tool
technology to produce a 1536-well plate (four-fold well
density of a 384-well plate) in white opaque and black
polystyrene with injection molded quality. The total
volume of the square wells is approximately 13 gl, the
well spacing is 2.25 mm.
Even with sophisticated techniques for high precision
molds, the latest software for injection molding machines,
and resins with excellent flow properties, it is merely
impossible to manufacture ultra-high density plates in the
gl-range with more than 6144 wells in a technically
traditional way.
This presentation focused on several novel microplates
ranging from 96 up to 6144 wells which have been
recently developed to cover existing and future demands.
These include thin-walled clear bottom plates with
excellent optical properties and quenched crosstalk,
UV-transparent plates with a superior transmission
window down to 250 nm and high chemical resistance.
High-throughput, mechanism-based screening
techniques for discovering novel agrochemicals
James c. Walsh, American Cyanamid Company, Princeton,
USA
A variety of screening strategies can be employed by
discovering novel agrochemicals such as fungicides, in-
secticides, herbicides and antiparasites. Traditionally,
random evaluation of chemical and natural products
samples has been used in assay systems ranging from
greenhouse testing down to in vitro microplate screening.
This task can be formidable depending upon the size of
sample libraries and personnel resources available. One
important tool in the overall discovery process at
Cyanamid is the application of highly specific and
sensitive mechanism-based assays for the purpose of
identifying novel leads.
This paper described high throughput, agar-based
screening techniques successfully implemented in a de-
centralized screening environment where laboratory
space and staffing are limited. Through the prudent use
of automated and manual high density agar-based tech-
niques, multiple sources of samples can now be processed
and evaluated against multiple targets in a timely
fashion. Assay validation can be streamlined. The ad-
vantages and disadvantages of an agar-based screening
approach were discussed.
Automated solutions for achieving the goals
of high-throughput screening at Wyeth-Ayerst
Research
James La Rocque, Wyeth-Ayerst Research, Pearl River, VY,
USA
A commitment of resources to HTS at Wyeth-Ayerst has
resulted in an expansion of laboratory space and person-
nel, as well as the acquisition of efficient automation
necessary to achieve the goal of screening a 200000
sampling library in several different assay formats. The
implementation of a variety of screens on Zymark
integrated systems, as well as workstation-based ap-
proaches to screening were reviewed. The generation of
daughter sample plates on a dedicated Zymark system
were also reviewed.
A multipurpose dual assay robot for compound
handing and drug discovery
Brent T. Butler, Joan Frezza, and Julie j. Tomlinson,
GlaxoWellcome Inc., Research Triangle Park, NC, USA
The Zymark scheduling software PCS allows the robot
operator to program true multitasking into the system.
The ability to do more than one job a time (i.e.
compound handling and biochemical assays) provides
increased throughput. The system can perform both
compound handling and biochemical assays in parallel.
This paper covered onsite integration and implementa-
tion of the multifunctional system, as well as some
applications which have been employed by the system.
Robotic method for semi-automation of plasma
triglyceride structure analysis by lipase
R. O. Adlof, L. C. Copes and E. A. Emken, USDA, ARS,
NCA UR, Peoria, IL, USA
Our studies on the absorption and metabolism of trigly-
ceride (TG) positional isomers in human and animal
models required the analysis of isolated triglyceride
samples by lipase. The triglycerides of blood and isolated
blood fractions, mouse liver tissue, native/randomized
lard and soybean oil were extracted and treated with
lipase. The 2-monoglyceride (MG) fractions were sepa-
rated from TGs and diglycerides (DGs) on a Zymark
BenchMate Workstation by silica SPE (3ml Bond
Elute (C) columns). TLC was used to verify the complete-
ness of MG separation. Average recoveries (c. 40%) of
the 2-monoglycerides in > 95 purity were consistent with
published results. The isolated MGs were manually
converted to methyl esters. The workstation (hexane as
extracting solvent) was used to isolate the methyl ester
fractions from the reaction mixtures. The impact(s) of
solvent volumes, mixing times and sample sizes on MG
and ester recoveries was studied. Gas chromatography
was used to determine fatty acid compositions; percent
recoveries were calculated by the addition of known
weights of 17:0 and 21:0 internal standards to the
samples. Ester recoveries for the BenchMate Workstation
were dependent on the initial substrates and varied from
65% to >90% compared to manual extraction data.
Fatty acid compositions of ester samples isolated by
robotic methods agreed with 0.5% with samples isolated
by non-robotic means. Oxidation products were not a
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problem. Solvent removal from the isolated samples was
done with a Zymark TurboVap LV Evaporator Work-
station.
The utilization of multiple component analysis by
LC-MS/MS in in vivo pharmacokinetic screening
experiments early in the drug discovery process
Timothy V. Olah, Merck & Company, West Point, PA, USA
LC-MS/MS has been rapidly embraced by the pharma-
ceutical industry as the definitive method for the deter-
mination of drug levels in biological fluids obtained from
pharmacokinetic and toxicological studies. This tech-
nique has proven to be reliable, accurate and precise
for the determination of drugs and related substances
(metabolites and isotopes) in support of preclinical and
clinical studies. Our group has recently expanded the use
of quantitative LC-MS/MS into the area of discovering
new substances as potential drug candidates. It is well
documented that when used as an accurate mass detec-
tor, triple quadropole instruments have the ability to
simultaneously and specifically detect minute quantities
of closely related drug substances in the extracts of
biological fluids. As the development of synthetic tech-
niques advances, we have focused our attention on the
development and implementation of analytical methods
that can simultaneously measure plasma concentrations
of up to 22 drug candidates over a concentration range of
1-1000 ng m1-1 in single analytical occasions. The accu-
racy and precision of easy assay is determined following
the evaluation of results obtained from quality control
samples which are incorporated in each analysis.
This approach is used to support drug discovery by
rapidly providing pharmacokinetic data to a wide range
of compounds by either increasing the speed and effi-
ciency of analysing samples following the administration
of single components to multiple animals or, by the
rapid assessment of plasma levels determined for each
individual component following the administration of
multiple compounds to single animals. These co-admin-
istration studies are carried out using compounds that are
either synthesized individually and combined for dosing
to animals or, synthesized as intact combinatorial li-
braries consisting of up to 20 compounds.
Currently, there is great interest in establishing tech-
nology for automated high-throughput bioanalysis invol-
ving both pharmacokinetics and metabolic stability
within the pharmaceutical industry. There are several
advantages and disadvantages to incorporating multiple
component analysis into a bioanalytical laboratory.
These include the rapid generation of high quality
analytical data and the efficient use of animals and
instrument time, as well as the limitations of assay
sensitivity, the speed of data processing and time, as well
as the limitations of assay sensitivity, the speed of data
processing and reporting and the potential for drug
interactions complicating the interpretation of results.
All work presented was performed under Good Labora-
tory Practice (GLP) guidelines.
Precise bioanalysis using the RapidTrace work-
station: application to an HPLC-UV method for a
new antihistamine and an LC-MS/MS method for
polypeptide
Roger A. Coe, Hong Zhang, Mary E. Petersen, JeD. Moran,
Patrick Lin, and Jean W. Lee, MDS Harris, Lincoln, NE, USA
An automated SPE RapidTrace Workstation has been
used at MDS Harris for routine bioanalytical sample
analysis. Extraction of different types of analytes from
biological fluids using a variety of SPE columns has been
developed. Illustrations were given for two methods: a
new antihistamine extracted with C18 cartridge, isolated
and quantified by a heart-cut column-switching, ion-
pair, reversed-phased HPLC-UV method; and A poly-
peptide extracted with Water OasisTM cartridge and
quantified by a Perkin Elmer AP1300 LC-MS/MS in
the negative ion mode. The methods were validated and
applied to clinical sample analysis. The methods were
shown to be precise, accurate, rugged and highly pro-
ductive.
Robotics and information systems integration
Jean Mercier, The Surrey Research Park, Guildford, UK
The integration of the screening chain from preparation,
selection, assay run, acquisition, analysis, storage and
retrieval of information plays an important role in the
increase of the drug discovery productivity (through the
amount of accurate hits generated) in screening labora-
tories.
Data management software is not just a tool for the
management of compound related data (chemical and
biological). It is the central component of an information
management system used to facilitate research and R&D
decision-making, making it a decision enabling tool.
Being such an important and central tool in pharmaceu-
tical R&D, the quality of the data in data management
systems needs to be of the highest standards. The quality
of data is directly related to data integrity. However, the
control software in today’s automated platforms have not
been designed to sufficiently guarantee data integrity.
Sometimes no control is available at all or control is
maintained through sets of data files with one file
containing the linking information. Some systems provide
interpreted data (calculated results) only, with limited
possibilities to control and track raw data. IDBS and
Zymark have developed a standard interfacing scheme to
ensure the quality of data, data integrity and control and
tracking of raw data. The integration between informa-
tion system software and workflow controller software
have multiple applications. Control ofdata flow, increase
of data accuracy during process, increase of screening
throughput automation during the confirmation phase.
Modular workstations
phase synthesis
for automated solution
M. Brands, M. Es-Sayed, V. Grundel, P. Naab, T. Repp, U.
Rosentreter, C. Schmeck, R. Schmitz, W. Schrock, Bayer
Pharma-Research, Wuppertal, Germany
Workstations for parallel synthesis in solution and se-
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quential purification of precursors, templates and final
compounds were described. Automated processes are
worked off interactively with the user to maintain a high
degree of flexibility. Therefore, these workstations can be
used for methodology, preparation and purification of
larger and minor quantities.
Consequently these workstations are used, when small to
medium sized libraries are needed for immediate hit
evaluation and directed synthesis for lead structure
optimization.
Synthesis is accomplished on a liquid handler based
workstation, which is also used for methodology. This
workstation can handle air sensitive materials and covers
a temperature range tiom -20 to 150C. A number of
different reactions have been applied to the machine, of
which some were presented.
Depending on the scale the crude material is purified by
automated flash chromatography (20mg-10g) or auto-
mated HPLC (5-20rag.) For flash chromatography 11
samples can be purified sequentially in one run. Again a
liquid handler is used for fraction collection and sample
preparation for analysis or biological testing. By HPLC
up to 96 samples are separated in one run.
Partially automated processes simplify software and
hardware design dramatically and thereby handling
and maintenance, especially when interchangeable parts
are used. Special training is thereby reduced to a mini-
mum. The ultimate goal is to use such workstations
everywhere by everyone in chemistry.
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